US20060276512A1 - Fumagillol derivatives and preparing method thereof - Google Patents

Fumagillol derivatives and preparing method thereof Download PDF

Info

Publication number
US20060276512A1
US20060276512A1 US11/494,026 US49402606A US2006276512A1 US 20060276512 A1 US20060276512 A1 US 20060276512A1 US 49402606 A US49402606 A US 49402606A US 2006276512 A1 US2006276512 A1 US 2006276512A1
Authority
US
United States
Prior art keywords
fumagillol
acetyl
acid
acetyl fumagillol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/494,026
Inventor
Cheol-Kyu Han
Jeong-Hyeok Yoon
Seung-Moak Kim
Nam-Doo Kim
Byung-Ha Chang
Jee-Young Lee
Tae-Bo Sim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0060017A external-priority patent/KR100455900B1/en
Priority claimed from KR10-2002-0029915A external-priority patent/KR100483836B1/en
Application filed by Individual filed Critical Individual
Priority to US11/494,026 priority Critical patent/US20060276512A1/en
Priority to US11/603,688 priority patent/US20070149613A1/en
Publication of US20060276512A1 publication Critical patent/US20060276512A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention is directed to a fumagillol derivative or a pharmaceutically acceptable salt thereof, showing excellent angiogenesis inhibitory effect, with low toxicity; a preparation method thereof; and a pharmaceutical composition comprising the same.
  • Angiogenesis is a phenomenon of forming new vessels at the capillary level by a series of processes, such as proliferation, infiltration and transfer, and interactions of vein endothelial cells. This phenomenon is considered to be not only a normal physiological process but also a pathological process of various diseases. Angiogenesis, properly controlled by various physiological substances, is an important physiological process, which is seen upon healing of wounded parts or formation of uterine endothelia after birth or menstruation.
  • angiogenesis that excessively generates novel capillary vessels is regarded as a pathological condition.
  • Such angiogenesis is known to be closely associated with growth and metastasis of solid cancers, diabetic retinopathy, rheumatic arthritis and psoriasis [Billington, D. C. Drug Design and Discovery, (1991), 8, 3.].
  • angiogenesis inhibitory agent is responsible for decrease or inhibition of growth of solid cancers, resulting in blocking metastasis of solid cancer.
  • Such an angiogenesis inhibitory agent has a useful therapeutic effect for other inflammatory diseases, such as diabetic retinopathy, rheumatoid arthritis, psoriasis, etc, in addition to solid cancers.
  • European Pat. Nos. 0 354 787, 0 357 061 and 0 415 294, and Japanese Pat. No. JP-A01-233275 disclose fumagillol derivatives.
  • 6-amino-6-deoxyfumagillol Chem. Pharm. Bull., 40, 575-579 (1992)]
  • 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, 6-O-(N-substituted carbamoyl)fumagillol Chem. Pharm. Bull., 40, 96-101 (1992)] have angiogenesis inhibitory functions.
  • angiogenesis inhibitory agents exhibiting excellent angiogenesis inhibitory effect with less toxicity, and having novel chemical structure.
  • the present invention provides a fumagillol derivative represented by the following general formula I, or a pharmaceutically acceptable salt thereof: (wherein,
  • X and Y are linked together to form the oxyran ring, and B is —(C ⁇ O)—,
  • R 1 is selected from the group consisting of hydrogen; hydroxy; methyl; chlorine; methoxy; methylpropoxy; isopropoxy; allyloxy; propyloxy; acetoxy cyano; amino; dimethylaminomethyl; methylpropoxy; dimethylethoxy; 3,5-diisopropyl-4-methoxy; 3,5-dimethyl-4-methoxy; isopropyl-4-ethoxy; dimethylamino; ethylamino; methylenedioxy; nitro; acetoxy; trifluoromethyl; and hydroxyethoxy,
  • the fumagillol derivative of the above formula I has at least 6 chiral centers, as represented by the following formula, and in the scope of the present invention, each optical isomer or mixtures thereof is included:
  • the present invention further comprises 6-O-(chloro)acetyl fumagillol as an intermediate represented by the formula II, for use in preparation of the fumagillol derivative of the formula I:
  • the fumagillol derivative of the present invention may be used in a form of a pharmaceutically acceptable salt.
  • an acid addition salt formed by a pharmaceutically acceptable free acid is usefully used.
  • an inorganic acid and an organic acid may be used.
  • the inorganic acid include hydrochloric acid, bromic acid, sulfuric acid and phosphoric acid.
  • the organic acid is exemplified by citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, umaric acid, gluconic acid, methansulfonic acid, glyconic acid, succinic acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid or aspartic acid.
  • the present invention provides a method of preparing an acetyl fumagillol derivative and a pharmaceutically acceptable salt thereof, as represented by the following Reaction Scheme 1.
  • the preparation method of the fumagillol derivative compound in which B is —(C ⁇ O)— comprises the steps of:
  • the prepared compound of the formula la is treated with an acid, or reacted with a salt in the presence of an acid catalyst, to perform an oxyrane ring-opening reaction, thereby yielding the fumagillol derivative represented by the formula 1b, as shown in the following Reaction Scheme 2: (wherein, R 1 , X and Y are as defined above) Below, a description will be given of each step.
  • the compound of the formula 2 as a starting material is acylated with ⁇ -halocarboxylic acid derivative having high reactivity, in the presence of the base, to give the compound of the formula 3, as seen in the following Reaction Scheme 3.
  • the compound of the formula III is a fumagillol, which is a hydrolyzed product of fumagillin produced by microbial fermentation [Tarbell, D, S. et. al., J. Am. Chem, Soc., 83, 3096 (1961)]81).
  • the above ⁇ -halocarboxylic acid derivative is selected from among chloroacetyl chloride, chloroacetyl bromide, chloroacetyl iodide, and chloroacetyl fluoride, and used in the amount of 1-5 equivalents, preferably in 1-1.5 equivalents, based on the compound of the formula 2.
  • an acid anhydride, a mixed anhydride or an acid chloride may be commonly used, and preferably, tertiary amines, such as triethylamine, diisopropylethyl amine, pyridine, dimethylamino pyridine, etc., are used in the amount of 1-10 equivalents. More preferably, 1-3 equivalents of triethylamine, or dimethylaminopyridine is used.
  • the solvent used for acylation is selected from the group consisting of dimethylformamide, dichloromethane, chloroform, diethylether, tetrahydrofuran, dioxane, acetonitrile, benzene and toluene.
  • dimethylformamide, dichloromethane or tetrahydrofuran is used.
  • acylation is carried out at 0-50° C., preferably at 20-50° C.
  • the compound of the formula 3, obtained from the previous acylation step, is reacted with the compound of the formula 4 as the amine derivative, to yield the compound of the formula la having a substituted amine compound, as seen in the following Reaction Scheme 4.
  • R 1 is as defined above
  • the aromatic compound of the formula 4, used in the above substitution reaction, is used in the amount of 1-equivalents, preferably 1-3 equivalents, based on the compound of the formula 3.
  • amine compound aliphatic or aromatic amine compound can be used. Such derivatives are specifically stated in the examples of the present invention.
  • the solvent used in this substitution reaction is selected from the group consisting of dimethylformamide, dichloromethane, chloroform, diethylether, tetrahydrofuran, dioxane, acetonitrile, benzene and toluene. It is preferred that dimethylformamide, dichloromethane or tetrahydrofuran is used.
  • the substitution reaction is performed at 0-100° C., preferably at 20-50° C. 3) Oxyrane Ring-Opening Step
  • the acid used in the ring-opening reaction examples include hydrochloric acid, bromic acid or iodic acid.
  • the acid usable as the catalyst comprises acetic acid, sulfuric acid, para-toluene sulfonic acid, hydrochloric acid, phosphoric acid or nitric aicd.
  • acetic acid or hydrochloric acid is preferably used.
  • the salt used in this reaction is selected from the group consisting of bromolithium, chlorolithium, sodium chloride, potassium chloride, potassium bromide, sodium bromide, potassium iodide, sodium iodide and lithium iodide.
  • chlorolithium, bromolithium, lithium iodide or sodium hydrogen carbonate is selected from the group consisting of bromolithium, chlorolithium, sodium chloride, potassium chloride, potassium bromide, sodium bromide, potassium iodide, sodium iodide and lithium iodide.
  • the present invention provides a pharmaceutical composition for angiogenesis inhibition, comprising the fumagillol derivative of the formula I or a pharmaceutically acceptable salt thereof as an effective ingredient.
  • HUVECs human umbilical vein endothelial cells
  • the fumagillol derivative of the formula I can strongly inhibit proliferation of vein endothelial cells, thus having excellent angiogenesis inhibitory effect.
  • a fumagillol derivative can be usefully used for decreasing and inhibiting growth and metastasis of cancer as well as treating other various inflammatory diseases, including diabetic retinopathy, rheumatic arthritis and psoriasis.
  • the fumagillol derivative is usable as a cancer metastasis inhibitor, or a therapeutic agent against cancer, rheumatic arthritis, psoriasis and diabetic retinopathy.
  • mice With a view to evaluating general toxicity of the compound of the formula I according to the present invention, experiments on acute toxicity were carried out using mice. As a result, it was found that the half lethal dose (LD 50 ) of each compound upon single oral administration was not less than 2 g/kg, whereby the compound was evaluated as a very safe compound.
  • LD 50 half lethal dose
  • the compound of the formula I according to the present invention may be formulated, upon clinical administration, as a pharmaceutical solid, semi-solid or liquid type formulation which is suitable for oral or parenteral administration by blending this compound with a pharmaceutically acceptable inert carrier.
  • the pharmaceutical composition of the present invention is formulated into dosage form for oral administration, for instance, tablet, troches, lozenge, water- or oil-soluble suspension, prepared powder or grain, emulsion, hard or soft capsule, syrup or elixir.
  • binders such as lactose, sacharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; vehicles such as dicalcium phosphate; disintegrating agents, such as corn starch or sweet-potato starch; and lubricants, such as magnesium stearate, calcium stearate, sodium stearylfumaric acid or polyethyleneglycol wax.
  • liquid carriers including fatty oil may be further included, in addition to the above materials.
  • compositions for parenteral administration comprise sterile aqueous solution, water-insoluble solvent, suspension, emulsion, and lyophilized agent.
  • water-insoluble solvent and suspension use may be made of vegetable oil such as propylene glycol, polyethylene glycol, olive oil, and injection ester, such as ethyl oleate.
  • effective doses of the compound of the formula I according to the present invention may range from 0.2 to 2.0 mg/kg, and they can be administered in a single dose or in divided daily doses.
  • amount of the active ingredient actually administered ought to be determined in light of various relevant factors including constitutional peculiarity and body weight of the individual subject, kinds and severity of diseases, properties of dosage form, properties of medicinal administration, and administration period or interval.
  • 6-O-chloroacetyl fumagillol 160 mg
  • dimethylformamide 1 ml
  • 4-methoxyaniline 0.055 mg
  • the mixture was further with K 2 CO 3 (61.48 mg) and KI (73.84 mg) and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (166 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4,5-trimethoxyaniline (0.079 mg) was added. Then, this mixture was further added with K 2 CO 3 (63.78 mg) and KI (76.61 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (168 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 2,4-dimethoxyaniline (0.072 mg) was added. Then, the mixture was further added with K 2 CO 3 (64.54 mg) and KI (77.52 mg) and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (164 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4-dimethoxyaniline (0.07 mg) was added. Then, the mixture was added with K 2 CO 3 (63.01 mg) and KI (75.68 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (154 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4-dimethoxy-6-nitroaniline (0.085 mg). Then, the mixture was added with K 2 CO 3 (59.18 mg) and KI (71.08 mg) and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol 160 mg
  • dimethylformamide 1 ml
  • 3,4-dimethoxy-6-cyanoaniline 0.079 mg
  • the mixture was further added with K 2 CO 3 (61.48 mg) and KI (73.84 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (165 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-allyloxyaniline (0.085 mg) was added. The mixture was further added with K 2 CO 3 (63.40 mg) and KI (76.14 mg) and stirred at 70° C. for 7 hours.
  • 6-O-chloroacetyl fumagillol 160 mg
  • dimethylformamide 1 ml
  • 4-(2-acetoxyethoxy)aniline (0.08 mg) was added.
  • the mixture was further added with K 2 CO 3 (61.48 mg) and KI (73.84 mg) and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol 150 mg
  • dimethylformamide 1 ml
  • 3-cyano-4-methoxyaniline 0.062 mg
  • the mixture was further added with K 2 CO 3 (57.64 mg) and KI (69.22 mg) and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (153 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-(dimethylaminomethyl)-4-methoxyaniline (0.092 mg) was added. Then, the mixture was further added with K 2 CO 3 (58.79 mg) and KI (70.61 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (152 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-(2-methylpropoxy)aniline (0.07 mg) was added. This mixture was further added with K 2 CO 3 (58.41 mg) and KI (70.15 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (161 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-(isopropoxy)-4-methoxyaniline (0.081 mg) was added. This mixture was added with K 2 CO 3 (61.87 mg) and KI (74.3 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (154 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-(N,N-dimethylethoxy)aniline (0.077 mg) was added. This mixture was further added with K 2 CO 3 (59.18 mg) and KI (71.08 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol 160 mg
  • dimethylformamide 1 ml
  • 3,5-diisopropyl-4-methoxyaniline 0.092 mg
  • This mixture was further added with K 2 CO 3 (61.48 mg) and KI (73.84 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (155 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,5-dimethyl-4-methoxyaniline (0.065 mg) was added. This mixture was further added with K 2 CO 3 (59.56 mg) and KI (71.53 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol (158 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-isopropyl-4-ethoxy-6-methylaniline (0.101 mg) was added. This mixture was added with K 2 CO 3 (60.71 mg) and KI (72.91 mg), and stirred at 70° C. for 6 hours.
  • 6-O-chloroacetyl fumagillol 160 mg
  • dimethylformamide 1 ml
  • 4-propyloxyaniline 0.084 mg
  • K 2 CO 3 61.48 mg
  • KI 73.84 mg
  • 6-O-chloroacetyl fumagillol (157 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which aniline (0.04 mg) was added. This mixture was added with K 2 CO 3 (60.33 mg) and KI (72.46 mg), and stirred at 70° C. for 6 hours.
  • Each of the fumagillol derivatives, obtained from the above examples 1 and 2 was treated with an acid, or reacted with a salt in the presence of an acid catalyst, to perform an oxyrane ring-opening reaction.
  • 6-O-(3,4,5-trimethoxyaniline)acetyl fumagillol (100 mg), obtained from the above example 2, in tetrahydrofuran (10 ml), was added with hydrochloric acid (0.14 ml) and stirred for 32 hours. This mixture was added with water (10 ml) and ethyl acetate (100 ml). The organic layer was separated, washed with saturated brine (10 ml), dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with ethylamine (16 mg) and stirred at room temperature for 5 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (134 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with isopropylamine (22 mg) and stirred at room temperature for 5 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (131 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with propylamine (22 mg) and stirred at room temperature for 8 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (128 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 1-butylamine (26 mg) and stirred at room temperature for 5 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-methyl-butylamine (32 mg) and stirred at room temperature for 7 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2,2-dimethyl-propylamine (32 mg) and stirred at room temperature for 10 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 1-ethyl-propylamine (32 mg) and stirred at room temperature for 6 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (135 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 1-isopropyl-2-methyl-propylamine (43 mg) and stirred at room temperature for 10 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (134 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 3-methylbutylamine (48 mg) and stirred at room temperature for 5 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (129 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-methyl-allylamine (26 mg), and stirred at room temperature for 5 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (51.4 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclopropylamine (8 mg) and stirred at room temperature for 8 hours.
  • the reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (50.3 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclobutylamine (10 mg) and stirred at room temperature for 6 hours.
  • the reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (51.0 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclopentylamine (12 mg) and stirred at room temperature for 6 hours.
  • the reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (53.5 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclohexylamine (15 mg) and stirred at room temperature for 6 hours.
  • the reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (128 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 4-tert-butyl-cyclohexylamine (55 mg) and stirred at room temperature for 6 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (132 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-dimethylamino-1-methylethylamine (38 mg) and stirred at room temperature for 6 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • 6-O-chloroacetyl fumagillol (126 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-dimethyl-propylamine (36 mg) and stirred at room temperature for 7 hours.
  • the reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml).
  • the organic layer was dried over anhydrous magnesium sulfate and filtered.
  • Each of the fumagillol derivatives obtained from the above examples 63 and 64 was treated with the acid, or reacted with the salt in the presence of the acid catalyst, to perform the oxyrane ring-opening reaction.
  • 6-O-(cyclobutylamino)acetyl fumagillol (100 mg), obtained from the above example 64, in tetrahydrofuran (10 ml) was added with chlorolithium (48 mg) and acetic acid (0.12 ml), and stirred at 30° C. for 36 hours. The reaction was added with water (10 ml) and ethyl acetate (100 ml). The organic layer was separated, washed with saturated brine (10 ml), dried over anhydrous magnesium sulfate and filtered.
  • a tablet containing the fumagillol compound of the present invention as an effective ingredient was prepared according to the following processes.
  • the compound of the above example 1 was sieved, mixed with lactose, starch and pregelatinized corn starch. To the mixture, purified water was added in a suitable volume. The paste was granulated, dried, mixed with magnesium stearate, and then compressed, to obtain the tablet.
  • Such a tablet comprises the following components: Compound of example 1 5.0 mg Lactose BP 150.0 mg Starch BP 30.0 mg Pregelatinized corn starch BP 15.0 mg Magnesium stearate 1.0 mg
  • a capsule containing the fumagillol compound of the present invention as the effective ingredient was prepared as follows.
  • the compound of the example 1 was mixed with a predetermined amount of a vehicle and magnesium state. Thusly obtained mixture was filled in a gelatin capsule.
  • Such a capsule comprises the following components: Compound of the example 1 5.0 mg Starch 1500 100.0 mg Magnesium sterate BP 1.0 mg
  • An injection containing the fumagillol compound of the present invention as the effective ingredient was prepared as follows.
  • the compound of the example 1 was dissolved in a suitable volume of saline for injection BP.
  • the pH of the resultant solution was controlled with dilute hydrochloric acid BP to be 3.5, and then the solution volume was controlled with saline for injection BP.
  • the solution was filled in 5 ml type 1 ampule made of transparent glass, and the top of ampule was fused for sealing.
  • the solution contained in the ampule was autoclaved at 120° C. for at least 15 minutes to be sterilized, giving the injection.
  • Such an injection comprises the following components: Compound of example 1 100 ⁇ g/ml Dilute hydrochloric acid BP to be pH 3.5 Saline for injection BP maximal 1 ml
  • HUVECs human umbilical vein endothelial
  • the HUVECs were added to M199 medium supplemented with 20% FBS (fetal bovine serum), 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 1.5 g/L sodium bicarbonate, 0.1 mg/ml endothelial cell growth supplement (Sigma) and 0.1 mg/ml heparin (Sigma), after which the cells were incubated in an incubator at 37° C. under 5% CO 2 . Cells were subcultured a maximum of 8 times before being discarded.
  • FBS fetal bovine serum
  • penicillin 100 ⁇ g/ml
  • streptomycin 100 ⁇ g/ml streptomycin
  • 1.5 g/L sodium bicarbonate 0.1 mg/ml endothelial cell growth supplement
  • 0.1 mg/ml heparin Sigma
  • the inventive compound was dissolved in DMSO and its concentration was adjusted from 10 mM to 1 mM.
  • Cells were aliquotted to 96 well plates at a density of 2 ⁇ 10 3 cells per well and incubated for about 12-24 hours to be properly attached to the plate. Thereafter, the medium was replaced with new medium.
  • the cells were treated with the compound obtained from each of the above examples at various concentration ranges of from 10 ⁇ M to 0.001 ⁇ M, and cultured for 2-3 days, followed by removing 100 ⁇ l of the medium from each well.
  • TNP-470 29 EX. 1 0.0071 EX. 2 0.15 EX. 3 0.09 EX. 4 0.08 EX. 5 142 EX. 6 19 EX. 7 21 EX. 8 42 EX. 9 0.63 EX. 10 0.06 EX. 11 0.08 EX. 12 0.07 EX. 13 0.016 EX. 14 14 EX. 15 0.06 EX. 16 0.17 EX. 17 0.61 EX. 18 17 EX. 19 174 EX. 20 162 EX. 21 185 EX. 22 179 EX. 23 0.24 EX. 24 181 EX.
  • EX. 25 0.31 EX. 26 179 EX. 27 88 EX. 28 102 EX. 29 178 EX. 30 0.09 EX. 31 0.06 EX. 32 128 EX. 33 109 EX. 34 98 EX. 35 116 EX. 36 0.021 EX. 37 0.017 EX. 38 0.019 EX. 39 0.019 EX. 40 0.18 EX. 41 20 EX. 42 12 EX. 43 2400 EX. 44 3200 EX. 45 370 EX. 46 2600 EX. 47 16 EX. 48 3000 EX. 49 44 EX. 50 24 EX. 51 32000 EX. 52 290 EX. 53 162 EX. 54 11 EX. 55 17 EX. 56 28 EX.
  • the inventive compound exhibits superior inhibitory effect on cell proliferation, compared to conventionally known fumagillin.
  • the compound in which R 1 is aromatic is superior in angiogenesis inhibitory effect to the compound in which R 1 is aliphatic.
  • 6-O-(4-methoxyaniline)acetyl fumagillol of the above example 1 has excellent inhibitory effect, 2000 times greater than known TNP-470.
  • 6-O-(cyclopropylamino)acetyl fumagillol and 6-O-(4-(cyclobutylamino)acetyl fumagillol of the above examples 63 and 64, respectively, are 100-1000 times higher in inhibitory effect on HUVEC, compared to TNP-470.
  • the present compounds did not show toxicity up to the amounts of 2 g/kg for all rats, and the minimal lethal dose (LD 50 ) of each compound in case of oral administration was 2 g/kg or more, thus the present compound was evaluated as a safe compound.
  • LD 50 minimal lethal dose
  • the compound of the formula I of the present invention is advantageous in light of excellent angiogenesis inhibitory effect and low toxicity, and is usefully applicable as an angiogenesis inhibitory agent.
  • the inventive compound can inhibit cancer metastasis and treat cancer, rheumatic arthritis, psoriasis and diabetic retinopathy, which are associated with angiogenesis regarded as a pathogenic phenomenon.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angiogenesis, and also a method for preparing the same.

Description

    TECHNICAL FIELD
  • The present invention is directed to a fumagillol derivative or a pharmaceutically acceptable salt thereof, showing excellent angiogenesis inhibitory effect, with low toxicity; a preparation method thereof; and a pharmaceutical composition comprising the same.
    • PRIOR ART
  • Angiogenesis is a phenomenon of forming new vessels at the capillary level by a series of processes, such as proliferation, infiltration and transfer, and interactions of vein endothelial cells. This phenomenon is considered to be not only a normal physiological process but also a pathological process of various diseases. Angiogenesis, properly controlled by various physiological substances, is an important physiological process, which is seen upon healing of wounded parts or formation of uterine endothelia after birth or menstruation.
  • However, in the uncontrolled state, angiogenesis that excessively generates novel capillary vessels is regarded as a pathological condition. Such angiogenesis is known to be closely associated with growth and metastasis of solid cancers, diabetic retinopathy, rheumatic arthritis and psoriasis [Billington, D. C. Drug Design and Discovery, (1991), 8, 3.].
  • Much research on inhibition of such angiogenesis regarded as a pathological condition has been performed. Judah Folkman of the Medical College of Harvard University suggested a new concept of treating solid cancer by inhibiting angiogenesis in 1971 [J. Folkman, New Engl. Med., 185 (1971), 1182-1185]. In other words, an angiogenesis inhibitory agent is responsible for decrease or inhibition of growth of solid cancers, resulting in blocking metastasis of solid cancer. Such an angiogenesis inhibitory agent has a useful therapeutic effect for other inflammatory diseases, such as diabetic retinopathy, rheumatoid arthritis, psoriasis, etc, in addition to solid cancers.
  • Compounds inhibiting angiogenesis have been developed through many efforts up to the present, and so various compounds are known as novel angiogenesis inhibitory agents.
  • In this regard, European Pat. Nos. 0 354 787, 0 357 061 and 0 415 294, and Japanese Pat. No. JP-A01-233275 disclose fumagillol derivatives.
  • Further, it has been reported that 6-amino-6-deoxyfumagillol [Chem. Pharm. Bull., 40, 575-579 (1992)], 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, 6-O-(N-substituted carbamoyl)fumagillol [Chem. Pharm. Bull., 40, 96-101 (1992)] have angiogenesis inhibitory functions.
  • However, there is required a continuous development of angiogenesis inhibitory agents exhibiting excellent angiogenesis inhibitory effect with less toxicity, and having novel chemical structure.
    • DISCLOSURE OF THE INVENTION
  • Leading to the present invention, the intensive and thorough research into novel compounds having high inhibitory effect on angiogenesis, carried out by the present inventors, resulted in the finding that an aniline derivative having various substituents can be introduced to a known fumagillol, whereby a compound of the formula I, which has angiogenesis inhibitory effect and low toxicity, can be prepared.
  • It is therefore an object of the present invention to provide a fumagillol derivative or a pharmaceutically acceptable salt thereof, exhibiting excellent angiogenesis inhibitory effect.
  • It is another object of the present invention to provide a method of preparing such a fumagillol derivative.
  • It is a further object of the present invention to provide a pharmaceutical composition for angiogenesis inhibition, usable as an angiogenesis inhibitor, comprising a fumagillol derivative or a pharmaceutically acceptable salt thereof as a useful ingredient.
  • The above objects are achieved by providing the fumagillol derivative or the pharmaceutically acceptable salt thereof of the present invention.
    • BEST MODES FOR CARRYING OUT THE INVENTION
  • The present invention provides a fumagillol derivative represented by the following general formula I, or a pharmaceutically acceptable salt thereof:
    Figure US20060276512A1-20061207-C00001
    (wherein,
      • X is ‘OH and Y is halogen, or X and Y are linked together to form an oxyrane ring,
      • B represents —(C═O)— or —CH2—,
      • R1 represents hydrogen; hydroxy; —CN; —NO2; —CF3; formyl; C1-C4 thioalkyl; acetamido; acetoxy; C1-C6 alkyl; C1-C4 aminoalkyl; C1-C4 alkylaminoalkyl; C1-C4 dialkylaminoalkyl; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 hydroxyalkyl; C1-C4 alkyloxycarboxylic acid, or
        Figure US20060276512A1-20061207-C00002
      • in which R2, R3, R4, R5 and R6, which are the same or different, each represents hydrogen; hydroxy; —CN; —NO2; —CF3; formyl; C1-C4 thioalkyl; acetamido; acetoxy; C1-C6 alkyl; C1-C4 aminoalkyl; C1-C4 alkylaminoalkyl; C1-C4 dialkylaminoalkyl; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 hydroxyalkyl; or C1-C4 alkyloxycarboxylic acid; or, R2 and R3, R3 and R4, R4 and R5, or R5 and R6, are linked together to form a C1-C3 alkylene dioxy ring, and
      • Z1, Z2, Z3, Z4 and Z5 each represent carbon or nitrogen).
  • Preferably, X and Y are linked together to form the oxyran ring, and B is —(C═O)—,
      • R1 is hydrogen; hydroxy; —CN; —NO2; —CF3; formyl; acetamido; acetoxy; C1-C6 alkyl; C1-C4 aminoalkyl; C1-C4 alkylaminoalkyl; C1-C4 dialkylaminoalkyl; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 hydroxyalkyl; C1-C4 alkyloxycarboxylic acid, or
      • R2, R3, R4, R5 and R6, which are the same or different, each represents hydrogen; hydroxy; —CN; —NO2; —CF3; formyl; acetamido; acetoxy; C1-C6 alkyl; C1-C4 aminoalkyl; C1-C4 alkylaminoalkyl; C1-C4 dialkylaminoalkyl; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 hydroxyalkyl; or C1-C4 alkyloxycarboxylic acid, or
      • R2 and R3, R3 and R4, R4 and R5, or R5 and R6 are linked together to form the C1-C3 alkylene dioxy ring, and
      • Z1, Z2, Z3, Z4 and Z5 each represent carbon or nitrogen.
  • More preferably, R1 is selected from the group consisting of hydrogen; hydroxy; methyl; chlorine; methoxy; methylpropoxy; isopropoxy; allyloxy; propyloxy; acetoxy cyano; amino; dimethylaminomethyl; methylpropoxy; dimethylethoxy; 3,5-diisopropyl-4-methoxy; 3,5-dimethyl-4-methoxy; isopropyl-4-ethoxy; dimethylamino; ethylamino; methylenedioxy; nitro; acetoxy; trifluoromethyl; and hydroxyethoxy,
      • R2, R3, R4, R5 and R6 is independently selected from the group consisting of hydrogen; hydroxy; methyl; chlorine; methoxy; methylpropoxy; isopropoxy; allyloxy; propyloxy; acetoxy cyano; amino; dimethylaminomethyl; methylpropoxy; dimethylethoxy; 3,5-diisopropyl-4-methoxy; 3,5-dimethyl-4-methoxy; isopropyl-4-ethoxy; dimethylamino; ethylamino; methylenedioxy; nitro; acetoxy; trifluoromethyl; and hydroxyethoxy, and
      • Z1, Z2, Z3 Z4 and Z5 each represent carbon or nitrogen.
  • The fumagillol derivative of the above formula I has at least 6 chiral centers, as represented by the following formula, and in the scope of the present invention, each optical isomer or mixtures thereof is included:
    Figure US20060276512A1-20061207-C00003
  • In addition, the present invention further comprises 6-O-(chloro)acetyl fumagillol as an intermediate represented by the formula II, for use in preparation of the fumagillol derivative of the formula I:
    Figure US20060276512A1-20061207-C00004
  • Among the compounds of the formula I, preferred are:
      • 1) 6-O-(4-methoxyaniline)acetyl fumagillol;
  • 2) 6-O-(3,4,5-trimethoxyaniline)acetyl fumagillol;
  • 3) 6-O-(2,4-dimethoxyaniline)acetyl fumagillol;
  • 4) 6-O-(3,4-dimethoxyaniline)acetyl fumagillol;
  • 5) 6-O-(3,4-dimethoxy-6-nitroaniline)acetyl fumagillol;
  • 6) 6-O-(3,4-dimethoxy-6-cyanoaniline)acetyl fumagillol;
  • 7) 6-O-(4-allyloxyaniline)acetyl fumagillol;
  • 8) 6-O-(4-(2-acetoxyethoxy)aniline)acetyl fumagillol;
  • 9) 6-O-(3-cyano-4-methoxyaniline)acetyl fumagillol;
  • 10) 6-O-(3-(dimethylaminomethyl)-4-methoxyaniline)acetyl fumagillol;
  • 11) 6-O-(4-(2-methylpropoxyaniline)acetyl fumagillol;
  • 12) 6-O-(3-isopropoxy-4-methoxyaniline)acetyl fumagillol;
  • 13) 6-O-(4-(N,N-dimethylethoxy)aniline)acetyl fumagillol;
  • 14) 6-O-(3,5-diisopropyl-4-methoxyaniline)acetyl fumagillol;
  • 15) 6-O-(3,5-dimethyl-4-methoxyaniline)acetyl fumagillol;
  • 16) 6-O-(3-isopropyl-4-ethoxy-6-methylaniline)acetyl fumagillol;
  • 17) 6-O-(4-propyloxyaniline)acetyl fumagillol;
  • 18) 6-O-(aniline)acetyl fumagillol;
  • 19) 6-O-(4-chloroaniline)acetyl fumagillol;
  • 20) 6-O-(4-dimethylaminoaniline)acetyl fumagillol;
  • 21) 6-O-(4-hydroxyaniline)acetyl fumagillol;
  • 22) 6-O-(4-aminoaniline)acetyl fumagillol;
  • 23) 6-O-(3,4-methylenedioxyaniline)acetyl fumagillol;
  • 24) 6-O-(4-nitroaniline)acetyl fumagillol;
  • 25) 6-O-(2,3,4-trimethoxy-6-aminoaniline)acetyl fumagillol;
  • 26) 6-O-(4-acetoxy-3,5-dimethoxyaniline)acetyl fumagillol;
  • 27) 6-O-(3,4-dimethoxy-5-hydroxyaniline)acetyl fumagillol;
  • 28) 6-O-(4-dimethylaminoethoxyaniline)acetyl fumagillol;
  • 29) 6-O-(4-ethylaminoaniline)acetyl fumagillol;
  • 30) 6-O-(4-ethylaminoethoxyaniline)acetyl fumagillol;
  • 31) 6-O-(3-dimethylaminomethyl-4-methoxyaniline)acetyl fumagillol;
  • 32) 6-O-(4-trifluoromethylaniline)acetyl fumagillol;
  • 33) 6-O-(4-acetoxy aniline)acetyl fumagillol;
  • 34) 6-O-(4-cyanoaniline)acetyl fumagillol;
  • 35) 6-O-(4-hydroxyethoxyaniline)acetyl fumagillol;
  • 36) 6-O-(5-amino-2-methoxypyridine)acetyl fumagillol;
  • 37) 6-O-(5-methoxypyrimidine-2-amino)acetyl fumagillol;
  • 38) 6-O-(3-methoxy-6-aminopyridazine)acetyl fumagillol;
  • 39) 4-((4-methoxyaniline)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;
  • 40) 4-((3,4,5-trimethoxyaniline)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;
  • 41) 6-O-(ethylamino)acetyl fumagillol;
  • 42) 6-O-(isopropyl amino)acetyl fumagillol;
  • 43) 6-O-(1-propyl amino)acetyl fumagillol;
  • 44) 6-O-(1-butyl amino)acetyl fumagillol;
  • 45) 6-O-(sec-butyl amino)acetyl fumagillol;
  • 46) 6-O-(2-methyl-butylamino)acetyl fumagillol;
  • 47) 6-O-(t-butyl amino)acetyl fumagillol;
  • 48) 6-O-(pentyl amino)acetyl fumagillol;
  • 49) 6-O-(1-methyl-butyl amino)acetyl fumagillol;
  • 50) 6-O-(1-ethyl-propyl amino)acetyl fumagillol;
  • 51) 6-O-(1-methyl-pentylamino)acetyl fumagillol;
  • 52) 6-O-(1,2-dimethyl-butylamino)acetyl fumagillol;
  • 53) 6-O-(1,2,2-trimethyl-propylamino)acetyl fumagillol;
  • 54) 6-O-(l-isopropyl-2-methylpropylamino)acetyl fumagillol;
  • 55) 6-O-(3-methylbutylamino)acetyl fumagillol;
  • 56) 6-O-(2-methylallylamino)acetyl fumagillol;
  • 57) 6-O-(4-methyl-hepta-2,4-dienylamino)acetyl fumagillol;
  • 58) 6-O-(1,5-dimethyl-4-hexenylamino)acetyl fumagillol;
  • 59) 6-O-(1,1-dimethyl-2-propynylamino)acetyl fumagillol;
  • 60) 6-O-(prop-2-enylamino)acetyl fumagillol;
  • 61) 6-O-(2-bromo-ethylamino)acetyl fumagillol;
  • 62) 6-O-(chloroethynylamino)acetyl fumagillol;
  • 63) 6-O-(cyclopropylamino)acetyl fumagillol;
  • 64) 6-O-(cyclobutylamino)acetyl fumagillol;
  • 65) 6-O-(cyclopentylamino)acetyl fumagillol;
  • 66) 6-O-(cyclohexylamino)acetyl fumagillol;
  • 67) 6-O-(4-tert-butylcyclohexylamino)acetyl fumagillol;
  • 68) 6-O-(2-dimethylamino-1-methylethylamino)acetyl fumagillol;
  • 69) 6-O-(2-dimethylamino-propylamino)acetyl fumagillol;
  • 70) 6-O-(2-methoxy-2-methyl-propylamino)acetyl fumagillol;
  • 71) 6-O-(2-oxo-propylamine)acetyl fumagillol;
  • 72) 6-O-(1,1-dimethyl-3-oxobutylamino)acetyl fumagillol;
  • 73) 6-O-(ethyl-2-aminoacetate)acetyl fumagillol;
  • 74) 6-O-(alanine-methylesteramino)acetyl fumagillol;
  • 75) 6-O-(methyl-2-amino-3,3-dimethylbutanoate)acetyl fumagillol;
  • 76) 6-O-(allylglycine-methylester)acetyl fumagillol;
  • 77) 6-O-(2,2-dimethoxy-ehtylamino)acetyl fumagillol;
  • 78) 4-((cyclopropylamino)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol;
  • 79) 4-((cyclobutylamino)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol; and
  • 80) 6-O-(chloro)acetyl fumagillol.
  • Among the compounds of the formula I, most preferred are:
  • 1) 6-O-(4-methoxyaniline)acetyl fumagillol;
  • 2) 6-O-(3,4,5-trimethoxyaniline)acetyl fumagillol;
  • 3) 6-O-(4-(N,N-dimethylethoxy)aniline)acetyl fumagillol;
  • 4) 6-O-(cyclopropylamino)acetyl fumagillol;
  • 5) 6-O-(cyclobutylamino)acetyl fumagillol;
  • 6) 4-((cyclopropylamino)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol; and
  • 7) 4-((cyclobutylamino)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol.
  • Structural formulas of the above compounds are shown in Tables 1a to 1d, below.
    TABLE 1a
    Figure US20060276512A1-20061207-C00005
    Ex.1
    Figure US20060276512A1-20061207-C00006
    Ex.2
    Figure US20060276512A1-20061207-C00007
    Ex.3
    Figure US20060276512A1-20061207-C00008
    Ex.4
    Figure US20060276512A1-20061207-C00009
    Ex.5
    Figure US20060276512A1-20061207-C00010
    Ex.6
    Figure US20060276512A1-20061207-C00011
    Ex.7
    Figure US20060276512A1-20061207-C00012
    Ex.8
    Figure US20060276512A1-20061207-C00013
    Ex.9
    Figure US20060276512A1-20061207-C00014
    Ex.10
    Figure US20060276512A1-20061207-C00015
    Ex.11
    Figure US20060276512A1-20061207-C00016
    Ex.12
    Figure US20060276512A1-20061207-C00017
    Ex.13
    Figure US20060276512A1-20061207-C00018
    Ex.14
    Figure US20060276512A1-20061207-C00019
    Ex.15
    Figure US20060276512A1-20061207-C00020
    Ex.16
    Figure US20060276512A1-20061207-C00021
    Ex.17
    Figure US20060276512A1-20061207-C00022
    Ex.18
    Figure US20060276512A1-20061207-C00023
    Ex.19
    Figure US20060276512A1-20061207-C00024
    Ex.20
    Figure US20060276512A1-20061207-C00025
  • TABLE 1b
    Figure US20060276512A1-20061207-C00026
    Ex.21
    Figure US20060276512A1-20061207-C00027
    Ex.22
    Figure US20060276512A1-20061207-C00028
    Ex.23
    Figure US20060276512A1-20061207-C00029
    Ex.24
    Figure US20060276512A1-20061207-C00030
    Ex.25
    Figure US20060276512A1-20061207-C00031
    Ex.26
    Figure US20060276512A1-20061207-C00032
    Ex.27
    Figure US20060276512A1-20061207-C00033
    Ex.28
    Figure US20060276512A1-20061207-C00034
    Ex.29
    Figure US20060276512A1-20061207-C00035
    Ex.30
    Figure US20060276512A1-20061207-C00036
    Ex.31
    Figure US20060276512A1-20061207-C00037
    Ex.32
    Figure US20060276512A1-20061207-C00038
    Ex.33
    Figure US20060276512A1-20061207-C00039
    Ex.34
    Figure US20060276512A1-20061207-C00040
    Ex.35
    Figure US20060276512A1-20061207-C00041
    Ex.36
    Figure US20060276512A1-20061207-C00042
    Ex.37
    Figure US20060276512A1-20061207-C00043
    Ex.38
    Figure US20060276512A1-20061207-C00044
    Ex.39
    Figure US20060276512A1-20061207-C00045
    Ex.40
    Figure US20060276512A1-20061207-C00046
  • TABLE 1c
    Figure US20060276512A1-20061207-C00047
    Ex.41
    Figure US20060276512A1-20061207-C00048
    Ex.42
    Figure US20060276512A1-20061207-C00049
    Ex.43
    Figure US20060276512A1-20061207-C00050
    Ex.44
    Figure US20060276512A1-20061207-C00051
    Ex.45
    Figure US20060276512A1-20061207-C00052
    Ex.46
    Figure US20060276512A1-20061207-C00053
    Ex.47
    Figure US20060276512A1-20061207-C00054
    Ex.48
    Figure US20060276512A1-20061207-C00055
    Ex.49
    Figure US20060276512A1-20061207-C00056
    Ex.50
    Figure US20060276512A1-20061207-C00057
    Ex.51
    Figure US20060276512A1-20061207-C00058
    Ex.52
    Figure US20060276512A1-20061207-C00059
    Ex.53
    Figure US20060276512A1-20061207-C00060
    Ex.54
    Figure US20060276512A1-20061207-C00061
    Ex.55
    Figure US20060276512A1-20061207-C00062
    Ex.56
    Figure US20060276512A1-20061207-C00063
    Ex.57
    Figure US20060276512A1-20061207-C00064
    Ex.58
    Figure US20060276512A1-20061207-C00065
    Ex.59
    Figure US20060276512A1-20061207-C00066
    Ex.60
    Figure US20060276512A1-20061207-C00067
  • TABLE 1d
    Figure US20060276512A1-20061207-C00068
    Ex.61
    Figure US20060276512A1-20061207-C00069
    Ex.62
    Figure US20060276512A1-20061207-C00070
    Ex.63
    Figure US20060276512A1-20061207-C00071
    Ex.64
    Figure US20060276512A1-20061207-C00072
    Ex.65
    Figure US20060276512A1-20061207-C00073
    Ex.66
    Figure US20060276512A1-20061207-C00074
    Ex.67
    Figure US20060276512A1-20061207-C00075
    Ex.68
    Figure US20060276512A1-20061207-C00076
    Ex.69
    Figure US20060276512A1-20061207-C00077
    Ex.70
    Figure US20060276512A1-20061207-C00078
    Ex.71
    Figure US20060276512A1-20061207-C00079
    Ex.72
    Figure US20060276512A1-20061207-C00080
    Ex.73
    Figure US20060276512A1-20061207-C00081
    Ex.74
    Figure US20060276512A1-20061207-C00082
    Ex.75
    Figure US20060276512A1-20061207-C00083
    Ex.76
    Figure US20060276512A1-20061207-C00084
    Ex.77
    Figure US20060276512A1-20061207-C00085
    Ex.78
    Figure US20060276512A1-20061207-C00086
    Ex.79
    Figure US20060276512A1-20061207-C00087
    Inter- mediate
    Figure US20060276512A1-20061207-C00088
  • The fumagillol derivative of the present invention, represented by the formula I, may be used in a form of a pharmaceutically acceptable salt. In particular, an acid addition salt formed by a pharmaceutically acceptable free acid is usefully used. As the free acid, an inorganic acid and an organic acid may be used. Examples of the inorganic acid include hydrochloric acid, bromic acid, sulfuric acid and phosphoric acid. The organic acid is exemplified by citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, umaric acid, gluconic acid, methansulfonic acid, glyconic acid, succinic acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid or aspartic acid.
  • Additionally, the present invention provides a method of preparing an acetyl fumagillol derivative and a pharmaceutically acceptable salt thereof, as represented by the following Reaction Scheme 1.
  • Specifically, the preparation method of the fumagillol derivative compound in which B is —(C═O)—, comprises the steps of:
  • (a) acylating a compound of the formula 2 with α-halocarboxylic acid derivative in the presence of a base, to give a compound of the formula 3; and
  • (b) reacting the compound of the formula 3 with an amine compound of the formula 4, to prepare the fumagillol derivative represented by the formula la via substitution.
    Figure US20060276512A1-20061207-C00089
    (wherein, R1 is as defined above)
  • In the present invention, the prepared compound of the formula la is treated with an acid, or reacted with a salt in the presence of an acid catalyst, to perform an oxyrane ring-opening reaction, thereby yielding the fumagillol derivative represented by the formula 1b, as shown in the following Reaction Scheme 2:
    Figure US20060276512A1-20061207-C00090
    (wherein, R1, X and Y are as defined above) Below, a description will be given of each step.
  • (1) Acylation Step
  • The compound of the formula 2 as a starting material is acylated with α-halocarboxylic acid derivative having high reactivity, in the presence of the base, to give the compound of the formula 3, as seen in the following Reaction Scheme 3.
    Figure US20060276512A1-20061207-C00091
  • Specifically, the compound of the formula III is a fumagillol, which is a hydrolyzed product of fumagillin produced by microbial fermentation [Tarbell, D, S. et. al., J. Am. Chem, Soc., 83, 3096 (1961)]81).
    Figure US20060276512A1-20061207-C00092
  • The above α-halocarboxylic acid derivative is selected from among chloroacetyl chloride, chloroacetyl bromide, chloroacetyl iodide, and chloroacetyl fluoride, and used in the amount of 1-5 equivalents, preferably in 1-1.5 equivalents, based on the compound of the formula 2.
  • As for the base, an acid anhydride, a mixed anhydride or an acid chloride may be commonly used, and preferably, tertiary amines, such as triethylamine, diisopropylethyl amine, pyridine, dimethylamino pyridine, etc., are used in the amount of 1-10 equivalents. More preferably, 1-3 equivalents of triethylamine, or dimethylaminopyridine is used.
  • The solvent used for acylation is selected from the group consisting of dimethylformamide, dichloromethane, chloroform, diethylether, tetrahydrofuran, dioxane, acetonitrile, benzene and toluene. Preferably, dimethylformamide, dichloromethane or tetrahydrofuran is used.
  • As such, acylation is carried out at 0-50° C., preferably at 20-50° C.
  • 2) Halogen-Amine Substitution Step
  • The compound of the formula 3, obtained from the previous acylation step, is reacted with the compound of the formula 4 as the amine derivative, to yield the compound of the formula la having a substituted amine compound, as seen in the following Reaction Scheme 4.
    Figure US20060276512A1-20061207-C00093
    (wherein, R1 is as defined above) The aromatic compound of the formula 4, used in the above substitution reaction, is used in the amount of 1-equivalents, preferably 1-3 equivalents, based on the compound of the formula 3.
  • As for the amine compound, aliphatic or aromatic amine compound can be used. Such derivatives are specifically stated in the examples of the present invention.
  • The solvent used in this substitution reaction is selected from the group consisting of dimethylformamide, dichloromethane, chloroform, diethylether, tetrahydrofuran, dioxane, acetonitrile, benzene and toluene. It is preferred that dimethylformamide, dichloromethane or tetrahydrofuran is used.
  • The substitution reaction is performed at 0-100° C., preferably at 20-50° C. 3) Oxyrane Ring-Opening Step
  • The compound of the formula la, resulting from the above step, is treated with the acid, or reacted with the salt in the presence of the acid catalyst, to perform the oxyrane ring-opening reaction, thereby yielding the fumagillol derivative represented by the formula 1b, as in the following Reaction Scheme 5.
    Figure US20060276512A1-20061207-C00094
    (wherein, R1, X and Y4 are as defined above)
  • Examples of the acid used in the ring-opening reaction include hydrochloric acid, bromic acid or iodic acid. The acid usable as the catalyst comprises acetic acid, sulfuric acid, para-toluene sulfonic acid, hydrochloric acid, phosphoric acid or nitric aicd. Of the acid catalysts, acetic acid or hydrochloric acid is preferably used.
  • The salt used in this reaction is selected from the group consisting of bromolithium, chlorolithium, sodium chloride, potassium chloride, potassium bromide, sodium bromide, potassium iodide, sodium iodide and lithium iodide. Preferably, chlorolithium, bromolithium, lithium iodide or sodium hydrogen carbonate.
  • Meanwhile, the preparation method of the compound in which B is —CH2— is specifically shown in the following Reaction Scheme 6.
    Figure US20060276512A1-20061207-C00095
  • Further, the present invention provides a pharmaceutical composition for angiogenesis inhibition, comprising the fumagillol derivative of the formula I or a pharmaceutically acceptable salt thereof as an effective ingredient.
  • In order to investigate activity of the fumagillol derivative on cell growth, proliferation inhibition activity was measured using HUVECs (human umbilical vein endothelial cells). As the result, it was found that the inventive fumagillol derivative has superior growth inhibition effect, up to 2000 times greater than TNP-470, a conventional angiogenesis inhibitory agent.
  • Therefore, it is expected that the fumagillol derivative of the formula I can strongly inhibit proliferation of vein endothelial cells, thus having excellent angiogenesis inhibitory effect. Such a fumagillol derivative can be usefully used for decreasing and inhibiting growth and metastasis of cancer as well as treating other various inflammatory diseases, including diabetic retinopathy, rheumatic arthritis and psoriasis. Hence, the fumagillol derivative is usable as a cancer metastasis inhibitor, or a therapeutic agent against cancer, rheumatic arthritis, psoriasis and diabetic retinopathy.
  • With a view to evaluating general toxicity of the compound of the formula I according to the present invention, experiments on acute toxicity were carried out using mice. As a result, it was found that the half lethal dose (LD50) of each compound upon single oral administration was not less than 2 g/kg, whereby the compound was evaluated as a very safe compound.
  • The compound of the formula I according to the present invention may be formulated, upon clinical administration, as a pharmaceutical solid, semi-solid or liquid type formulation which is suitable for oral or parenteral administration by blending this compound with a pharmaceutically acceptable inert carrier.
  • The pharmaceutical composition of the present invention is formulated into dosage form for oral administration, for instance, tablet, troches, lozenge, water- or oil-soluble suspension, prepared powder or grain, emulsion, hard or soft capsule, syrup or elixir. For formulation of the tablet and capsule form, used are binders such as lactose, sacharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; vehicles such as dicalcium phosphate; disintegrating agents, such as corn starch or sweet-potato starch; and lubricants, such as magnesium stearate, calcium stearate, sodium stearylfumaric acid or polyethyleneglycol wax. In the case of capsule formulation, liquid carriers including fatty oil may be further included, in addition to the above materials.
  • Pharmaceutical preparations for parenteral administration comprise sterile aqueous solution, water-insoluble solvent, suspension, emulsion, and lyophilized agent. As the water-insoluble solvent and suspension, use may be made of vegetable oil such as propylene glycol, polyethylene glycol, olive oil, and injection ester, such as ethyl oleate.
  • In typical medical substances, effective doses of the compound of the formula I according to the present invention may range from 0.2 to 2.0 mg/kg, and they can be administered in a single dose or in divided daily doses. However, it should be understood by anyone skilled in the art that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including constitutional peculiarity and body weight of the individual subject, kinds and severity of diseases, properties of dosage form, properties of medicinal administration, and administration period or interval.
  • A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
    • EXAMPLE 1 Preparation of 6-O-(4-methoxyaniline)acetyl fumagillol
  • Step 1: (Acylation) Preparation of 6-O-chloroacetyl fumagillol
  • Fumagillol (500 mg) in dichloromethane (10 ml) was added with dimethylaminopyridine (432 mg) and chloroacetyl chloride (199 mg), and stirred at room temperature for 1 hour. The reaction was vacuum concentrated, to give the residue, which was then purified by silica gel column chromatography (ethyl acetate:n-hexane=1:4), yielding 270 mg of the title compound as a light yellow oil.
  • 1H-NMR (CDCl3) δ: 5.76-5.74 (m, 1H), 5.22 (br t, 1H, J=7.3 Hz) , 4.19 (s, 2H) , 3.71 (dd, 1H, J=2.8, 11.1 Hz), 3.47 (s, 3H), 3.01 (d, 1H, J=4.3 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.56 (d, 1H, J=4.3 Hz), 2.41-1.81 (m, 9H), 1.75 (s, 3H), 1.66 (s, 3H), 1.24 (s, 3H), 1.18-1.06 (m, 1H).
  • Step 2: (Substitution) Preparation of 6-O-(4-methoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (160 mg), obtained from the above step 1, was dissolved in dimethylformamide (1 ml), to which 4-methoxyaniline (0.055 mg) was added. The mixture was further with K2CO3 (61.48 mg) and KI (73.84 mg) and stirred at 70° C. for 6 hours.
  • Thereafter, the resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was separated, dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 112 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.57 (s, 2H), 5.70-5.73 (m, 1H), 5.19 (br t, 1H, J=7.3 Hz), 4.21 (s, 2H), 3.86 (s, 3H), 3.72 (dd, 1H, J=2.9, 11.1 Hz), 3.45 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.56 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.43-1.83 (m, 6H), 1.78 (s, 3H) 1.63 (s, 3H) 1.25 (s, 3H) 1.19-1.03 (m, 1H).
    • EXAMPLE 2 Preparation of 6-O-(3,4,5-trimethoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (166 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4,5-trimethoxyaniline (0.079 mg) was added. Then, this mixture was further added with K2CO3 (63.78 mg) and KI (76.61 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was separated, and dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 136 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.54 (s, 2H), 5.73-5.73 (m, 1H), 5.21 (br t, 1H, J=7.3 Hz), 4.21 (s, 2H), 3.89 (s, 9H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.44 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.43-1.83 (m, 6H), 1.75 (s, 3H) 1.67 (s, 3H) 1.23 (s, 3H) 1.15-1.04 (m, 1H).
    • EXAMPLE 3 Preparation of 6-O-(2,4-dimethoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (168 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 2,4-dimethoxyaniline (0.072 mg) was added. Then, the mixture was further added with K2CO3 (64.54 mg) and KI (77.52 mg) and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was separated, dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 140 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.57-6.48 (m, 3H), 5.73-5.71 (m, 1H), 5.24 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 3.91 (s, 6H), 3.72 (dd, 1H, J=2.9, 1.10 Hz), 3.49 (s, 3H), 3.01 (d, 1H, J=4.3 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.3 Hz), 2.43-1.83 (m, 6H), 1.77 (s, 3H) 1.66 (s, 3H) 1.24 (s, 3H) 1.15-1.01 (m, 1H).
    • EXAMPLE 4 Preparation of 6-O-(3,4-dimethoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (164 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4-dimethoxyaniline (0.07 mg) was added. Then, the mixture was added with K2CO3 (63.01 mg) and KI (75.68 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 132 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 6.54-6.47 (m, 3H), 5.73-5.69 (m, 1H), 5.21 (br t, 1H, J=7.2 Hz), 4.25 (s, 2H), 3.86 (s, 6H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.51 (s, 3H), 3.03 (d, 1H, J=4.2 Hz), 2.56 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.41-1.81 (m, 6H), 1.75 (s, 3H) 1.67 (s, 3H) 1.26 (s, 3H) 1.18-1.02 (m, 1H).
    • EXAMPLE 5 Preparation of 6-O-(3,4-dimethoxy-6-nitroaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (154 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4-dimethoxy-6-nitroaniline (0.085 mg). Then, the mixture was added with K2CO3 (59.18 mg) and KI (71.08 mg) and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 161 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.73-6.66 (m, 2H), 5.75-5.71 (m, 1H), 5.23 (br t, 1H, J=7.2 Hz), 4.27 (s, 2H), 3.93 (s, 6H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.49 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.43-1.83 (m, 6H), 1.75 (s, 3H) 1.64 (s, 3H) 1.25 (s, 3H) 1.18-1.03 (m, 1H).
    • EXAMPLE 6 Preparation of 6-O-(3,4-dimethoxy-6-cyanoaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (160 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,4-dimethoxy-6-cyanoaniline (0.079 mg) was added. The mixture was further added with K2CO3 (61.48 mg) and KI (73.84 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 128 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.77-6.64 (m, 2H), 5.73-5.70 (m, 1H), 5.21 (br t, 1H, J=7.2 Hz), 4.26 (s, 2H), 3.90 (s, 6H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.51 (s, 3H), 3.03 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz) , 2.54 (d, 1H, J=4.1 Hz), 2.46-1.80 (m, 6H), 1.76 (s, 3H) 1.66 (s, 3H) 1.23 (s, 3H) 1.19-1.04 (m, 1H).
    • EXAMPLE 7 Preparation of 6-O-(4-allyloxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (165 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-allyloxyaniline (0.085 mg) was added. The mixture was further added with K2CO3 (63.40 mg) and KI (76.14 mg) and stirred at 70° C. for 7 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 151 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 6.58-6.54 (m, 2H), 6.32-6.29 (m, 2H), 5.87-5.85 (m, 1H), 5.73-5.70 (m, 1H), 5.41-5.35 (m, 2H), 5.21 (br t, 1H, J=7.2 Hz), 4.61 (d, 2H, J=7.4 Hz), 4.26 (s, 2H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.51 (s, 3H), 3.03 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.1 Hz), 2.46-1.80 (m, 6H), 1.76 (s, 3H) 1.66 (s, 3H) 1.23 (s, 3H) 1.19-1.04 (m, 1H).
    • EXAMPLE 8 Preparation of 6-O-(4-(2-acetoxyethoxy)aniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (160 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-(2-acetoxyethoxy)aniline (0.08 mg) was added. Then, the mixture was further added with K2CO3 (61.48 mg) and KI (73.84 mg) and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 153 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 6.54-6.52 (m, 2H), 6.38-6.34 (m, 2H), 5.73-5.70 (m, 1H), 5.21 (br t, 1H, J=7.2 Hz), 4.52 (t, 2H, J=7.0 Hz), 4.29 (t, 2H, J=7.0 Hz), 4.24 (s, 2H), 3.73 (dd, 1H, J=2.9, 1.11 Hz), 3.53 (s, 3H), 3.01 (d, 1H, J=4.3 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.3 Hz), 2.45-1.82 (m, 6H), 2.02 (s, 3H), 1.79 (s, 3H) 1.65 (s, 3H) 1.24 (s, 3H) 1.17-1.02 (m, 1H).
    • EXAMPLE 9 Preparation of 6-O-(3-cyano-4-methoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (150 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-cyano-4-methoxyaniline (0.062 mg) was added. Then, the mixture was further added with K2CO3 (57.64 mg) and KI (69.22 mg) and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 124 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.77-6.64 (m, 3H), 5.73-5.70 (m, 1H), 5.21 (br t, 1H, J=7.2 Hz), 4.25 (s, 2H), 3.92 (s, 3H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.54 (s, 3H), 3.03 (d, 1H, J=4.1 Hz), 2.60 (t, 1H, J=6.4 Hz), 2.53 (d, 1H, J=4.1 Hz), 2.46-1.80 (m, 6H), 1.79 (s, 3H) 1.69 (s, 3H) 1.24 (s, 3H) 1.18-1.02 (m, 1H).
    • EXAMPLE 10 Preparation of 6-O-(3-(dimethylaminomethyl)-4-methoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (153 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-(dimethylaminomethyl)-4-methoxyaniline (0.092 mg) was added. Then, the mixture was further added with K2CO3 (58.79 mg) and KI (70.61 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 161 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.43-6.19 (m, 3H), 5.73-5.70 (m, 1H), 5.23 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 3.93 (s, 3H), 3.74 (dd, 1H, J=2.9, 11.1 Hz), 3.66 (s, 2H) , 3.52 (s, 3H) , 3.00 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.1 Hz), 2.46-1.80 (m, 6H), 2.26 (s, 6H), 1.78 (s, 3H) 1.66 (s, 3H) 1.25 (s, 3H) 1.16-1.04 (m, 1H).
    • EXAMPLE 11 Preparation of 6-O-(4-(2-methylpropoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (152 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-(2-methylpropoxy)aniline (0.07 mg) was added. This mixture was further added with K2CO3 (58.41 mg) and KI (70.15 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 123 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.59-6.55 (m, 2H), 6.37-6.33 (m, 2H), 5.74-5.71 (m, 1H), 5.25 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 3.91 (d, 2H, J=6.5 Hz), 3.74 (dd, 1H, J=2.9, 11.1 Hz), 3.52 (s, 3H), 3.03 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.1 Hz), 2.45-1.80 (m, 7H), 1.78 (s, 3H) 1.66 (s, 3H) 1.25 (s, 3H) , 1.19 (d, 6H, J=6.1 Hz) , 1.15-1.01 (m, 1H)
    • EXAMPLE 12 Preparation of 6-O-(3-isopropoxy-4-methoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (161 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-(isopropoxy)-4-methoxyaniline (0.081 mg) was added. This mixture was added with K2CO3 (61.87 mg) and KI (74.3 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 151 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.43-6.11 (m, 3H), 5.73-5.70 (m, 1H), 5.23 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 4.11 (q, 1H,J=6.7 Hz), 3.93 (s, 3H), 3.74 (dd, 1H, J=2.9, 1.11 Hz), 3.52 (s, 3H), 3.00 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.1 Hz), 2.46-1.80 (m, 6H), 1.78 (s, 3H) 1.66 (s, 3H), 1.40 (d, 6H, J=6.7 Hz), 1.25 (s, 3H) 1.16-1.04 (m, 1H).
    • EXAMPLE 13 Preparation of 6-O-(4-(N,N-dimethylethoxy)aniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (154 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-(N,N-dimethylethoxy)aniline (0.077 mg) was added. This mixture was further added with K2CO3 (59.18 mg) and KI (71.08 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 158 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.61-6.57 (m, 2H), 6.39-6.35 (m, 2H), 5.74-5.70 (m, 1H), 5.26 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 4.03 (t, 2H, J=6.8 Hz), 3.75 (dd, 1H, J=2.9, 1.11 Hz), 3.52 (s, 3H), 3.05 (d, 1H, J=4.1 Hz), 2.57 (t, 1H, J=6.4 Hz), 2.79 (t, 2H, J=6.8 Hz), 2.59 (s, 6H), 2.50 (d, 1H, J=4.1 Hz), 2.45-1.80 (m, 6H), 1.77 (s, 3H) 1.65 (s, 3H) 1.26 (s, 3H), 1.17-1.02 (m, 1H).
    • EXAMPLE 14 Preparation of 6-O-(3,5-diisopropyl-4-methoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (160 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,5-diisopropyl-4-methoxyaniline (0.092 mg) was added. This mixture was further added with K2CO3 (61.48 mg) and KI (73.84 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 171 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.58-6.54 (m, 2H), 5.74-5.71 (m, 1H), 5.25 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 3.91 (s, 3H), 3.74 (dd, 1H, J=2.9, 1.11 Hz), 3.52 (s, 3H), 3.19 (q, 2H, J=6.3 Hz), 3.03 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.1 Hz), 2.45-1.80 (m, 6H), 1.78 (s, 3H) 1.69 (s, 3H), 1.32 (d, 12H, J=6.3 Hz), 1.25 (s, 3H), 1.18-1.00 (m, 1H).
    • EXAMPLE 15 Preparation of 6-O-(3,5-dimethyl-4-methoxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (155 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3,5-dimethyl-4-methoxyaniline (0.065 mg) was added. This mixture was further added with K2CO3 (59.56 mg) and KI (71.53 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 145 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.56-6.51 (m, 2H), 5.75-5.72 (m, 1H), 5.27 (br t, 1H, J=7.2 Hz), 4.25 (s, 2H), 3.93 (s, 3H), 3.72 (dd, 1H, J=2.9, 1.11 Hz), 3.55 (s, 3H), 3.04 (d, 1H, J=4.1 Hz), 2.56 (t, 1H, J=6.4 Hz), 2.50 (d, 1H, J=4.1 Hz), 2.45-1.80 (m, 12H), 1.78 (s, 3H) 1.69 (s, 3H), 1.25 (s, 3H), 1.18-1.00 (m, 1H).
    • EXAMPLE 16 Preparation of 6-O-(3-isopropyl-4-ethoxy-6-methylaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (158 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 3-isopropyl-4-ethoxy-6-methylaniline (0.101 mg) was added. This mixture was added with K2CO3 (60.71 mg) and KI (72.91 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 166 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.54-6.51 (m, 2H), 5.75-5.72 (m, 1H), 5.27 (br t, 1H, J=7.2 Hz), 4.21 (s, 2H), 3.97 (q, 2H, J=6.2 Hz), 3.74 (dd, 1H, J=2.9, 1.11 Hz), 3.52 (s, 3H), 3.14 (q, 1H, J=6.5 Hz), 3.03 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.1 Hz), 2.45-1.80 (m, 9H), 1.78 (s, 3H) 1.69 (s, 3H), 1.35 (t, 3H, J=6.2 Hz), 1.28 (d, 6H, J=6.5 Hz), 1.25 (s, 3H), 1.18-1.00 (m, 1H).
    • EXAMPLE 17 Preparation of 6-O-(4-propyloxyaniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (160 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which 4-propyloxyaniline (0.084 mg) was added. This mixture was added with K2CO3 (61.48 mg) and KI (73.84 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The separated organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 105 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.63-6.58 (m, 2H), 6.40-6.36 (m, 2H), 5.74-5.71 (m, 1H), 5.25 (br t, 1H, J=7.2 Hz), 4.23 (s, 2H), 3.95 (t, 2H, J=6.8 Hz), 3.74 (dd, 1H, J=2.9, 1.11 Hz), 3.55 (s, 3H), 3.01 (d, 1H, J=4.1 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.52 (d, 1H, J=4.1 Hz), 2.45-1.82 (m, 6H), 1.77-1.74 (m, 5H) 1.68 (s, 3H) 1.26 (s, 3H), 1.15-1.01 (m, 4H).
    • EXAMPLE 18 Preparation of 6-O-(aniline)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (157 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), to which aniline (0.04 mg) was added. This mixture was added with K2CO3 (60.33 mg) and KI (72.46 mg), and stirred at 70° C. for 6 hours.
  • The resultant reaction was diluted with ethyl acetate (20 ml), and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The obtained filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 118 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 7.66-7.14 (m, 5H), 5.75-5.71 (m, 1H) , 5.20 (br t, 1H, J=7.3 Hz), 4.18 (s, 2H), 3.72 (dd, 1H, J=2.8, 11.1 Hz), 3.45 (s, 3H), 3.00 (d, 1H, J=4.3 Hz), 2.59 (t, 1H, J=6.4 Hz), 2.58 (d, 1H, J=4.3 Hz), 2.41-1.81 (m, 6H), 1.78 (s, 3H) 1.66 (s, 3H) , 1.26 (s, 3H) , 1.17-1.04 (m, 1H)
    • EXAMPLES 19-38
  • The fumagillol derivatives represented by the formula I were prepared in the same manner as in the above example 1, except that aromatic compounds were changed. The results are given in Table 2, below.
    TABLE 2
    EX. No. Fumagillol Derivative Aromatic Compound
    19 6-O-(4-chloroaniline)acetyl fumagillol 4-chloroaniline
    20 6-O-(4-dimethylaminoaniline)acetyl fumagillol 4-dimethylaminoaniline
    21 6-O-(4-hydroxyaniline)acetyl fumagillol 4-hydroxyaniline
    22 6-O-(4-aminoaniline)acetyl fumagillol 4-aminoaniline
    23 6-O-(3,4-methylenedioxyaniline)acetyl 3,4-methylenedioxyaniline
    fumagillol
    24 6-O-(4-nitroaniline)acetyl fumagillol 4-nitroaniline
    25 6-0-(2,3,4-trimethoxyaniline)acetyl 2,3,4-trimethoxyaniline
    fumagillol
    26 6-0-(4-acetoxy-3,5-dimethoxyaniline)acetyl 4-acetoxy-3,5-dimethoxyaniline
    fumagillol
    27 6-0-(3,4-dimethoxy-4-hydroxyaniline)acetyl 3,4-dimethoxy-4-hydroxyaniline
    fumagillol
    28 6-O-(4-dimethylaminoethoxyaniline)acetyl 4-dimethylaminoethoxyaniline
    fumagillol
    29 6-0-(4-ethylamino)acetyl fumagillol 4-ethylamino
    30 6-0-(4-ethylaminoaniline)acetyl fumagillol 4-ethylaminoaniline
    31 6-O-(3-dimethylaminomethyl-4- 3-dimethylaminomethyl-4-
    methoxyaniline)acetyl fumagillol methoxyaniline
    32 6-O-(4-trifluoromethylaniline)acetyl 4-trifluoromethylaniline
    fumagillol
    33 6-O-(4-acetoxyaniline)acetyl fumagillol 4-acetoxyaniline
    34 6-O-(4-cyanoaniline)acetyl fumagillol 4-cyanoaniline
    35 6-O-(4-hydroxyethoxyaniline)acetyl fumagillol 4-hydroxyethoxyaniline
    36 6-O-(5-amino-2-methoxypyridine)acetyl 5-amino-2-methoxypyridine
    fumagillol
    37 6-O-(5-methoxypyrimidine-2-amino)acetyl 5-methoxypyrimidine-2-amino
    fumagillol
    38 6-O-(3-methoxy-6-aminopyridazine)acetyl 3-methoxy-6-aminopyridazine
    fumagillol
  • Each of the fumagillol derivatives, obtained from the above examples 1 and 2, was treated with an acid, or reacted with a salt in the presence of an acid catalyst, to perform an oxyrane ring-opening reaction.
    • EXAMPLE 39 Preparation of 4-((4-methoxyaniline)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol
  • 6-O-(4-methoxyaniline)acetyl fumagillol (100 mg), obtained from the above example 1, was dissolved in tetrahydrofuran (10 ml), to which chlorolithium (48 mg) and acetic acid (0.12 ml) were added. This mixture was stirred at 30° C. for 36 hours. The resultant reaction was added with water (10 ml) and ethyl acetate (100 ml). The organic layer was separated, washed with saturated brine (10 ml), dried over anhydrous magnesium sulfate and filtered, followed by distilling off the solvent under reduced pressure. Then, thusly obtained residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:2), to give 85 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.57 (s, 2H), 5.70-5.73 (m, 1H), 5.19 (br t, 1H, J=7.3 Hz), 4.21 (s, 2H), 3.86 (3s, 9H), 3.72 (dd, 1H, J=2.6, 11.1 Hz), 3.45 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.56 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.43-1.83 (m, 6H), 1.78 (s, 3H) 1.63 (s, 3H) 1.25 (s, 3H) 1.19-1.03 (m, 1H).
    • EXAMPLE 40 Preparation of 4-((3,4,5-trimethoxyaniline)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol
  • 6-O-(3,4,5-trimethoxyaniline)acetyl fumagillol (100 mg), obtained from the above example 2, in tetrahydrofuran (10 ml), was added with hydrochloric acid (0.14 ml) and stirred for 32 hours. This mixture was added with water (10 ml) and ethyl acetate (100 ml). The organic layer was separated, washed with saturated brine (10 ml), dried over anhydrous magnesium sulfate and filtered. Then, the solvent was distilled off under reduced pressure, to give the residue, which was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:2), yielding 72 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 6.54 (s, 2H), 5.73-5.73 (m, 1H), 5.21 (br t, 1H, J=7.3 Hz), 4.21 (s, 2H), 3.89 (3s, 9H), 3.72 (dd, 1H, J=2.6, 1.11 Hz), 3.44 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.43-1.83 (m, 6H), 1.75 (s, 3H) 1.67 (s, 3H) 1.23 (s, 3H) 1.15-1.04 (m, 1H).
    • EXAMPLE 41 Preparation of 6-O-(ethylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with ethylamine (16 mg) and stirred at room temperature for 5 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 84 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.72-5.70 (m, 1H), 5.21 (br t, 1H, J=7.2 Hz), 3.67 (dd, 1H, J=2.8, 1.11 Hz), 3.58-3.39 (m, 5H), 3.48 (s, 3H), 3.00 (d, 1H, J=4.3 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.3 Hz), 2.50 (q, 2H, J=11.0 Hz), 2.41-1.81 (m, 9H), 1.73 (s, 3H), 1.66 (s, 3H), 1.25 (s, 3H), 1.18-1.05 (m, 4H), 1.00 (t, 3H, J=11.0 Hz).
    • EXAMPLE 42 Preparation of 6-O-(isopropylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (134 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with isopropylamine (22 mg) and stirred at room temperature for 5 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 93 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.71 (m, 1H) , 5.19 (br t, 1H, J=7.2 Hz), 3.65 (dd, 1H, J=2.8, 1.11 Hz), 3.56-3.37 (m, 5H), 3.47 (s, 3H), 3.02 (d, 1H, J=4.2 Hz), 2.59 (t, 1H, J=6.4 Hz), 2.55 (d, 1H, J=4.2 Hz), 2.50 (q, 1H, J=11.2 Hz), 2.44-1.82 (m, 9H) , 1.72 (s, 3H) , 1.64 (s, 3H) , 1.23 (s, 3H) , 1.13-1.05 (m, 7H), 1.01 (d, 1H, J=11.2 Hz).
    • EXAMPLE 43 Preparation of 6-O-(propylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (131 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with propylamine (22 mg) and stirred at room temperature for 8 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 98 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) 8 : 5.72-5.70 (m, 1H), 5.22 (br t, 1H, J=7.2 Hz), 3.65 (dd, 1H, J=2.8, 1.11 Hz), 3.59-3.40 (m, 5H), 3.46 (s, 3H), 3.00 (d, 1H, J=4.4 Hz), 2.56 (t, 1H, J=6.4 Hz), 2.55 (d, 1H, J=4.4 Hz), 2.51 (t, 2H, J=11.0 Hz), 2.40-1.79 (m, 9H), 1.75 (s, 3H), 1.67 (s, 3H), 1.24 (s, 3H), 1.20-1.05 (m, 6H).
    • EXAMPLE 44 Preparation of 6-O-(1-butylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (128 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 1-butylamine (26 mg) and stirred at room temperature for 5 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 102 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.71 (m, 1H), 5.21 (br t, 1H, J=7.2 Hz), 3.66 (dd, 1H, J=2.8, 11.1 Hz), 3.59-3.40 (m, 5H), 3.46 (s, 3H), 3.00 (d, 1H, J=4.3 Hz), 2.57 (t, 1H, J=6.3 Hz), 2.54 (d, 1H, J=4.3 Hz), 2.51 (t, 2H, J=11.0 Hz), 2.40-1.79 (m, 9H), 1.76 (s, 3H), 1.69 (s, 3H), 1.25 (s, 3H), 1.21-1.00 (m, 8H).
    • EXAMPLE 46 Preparation of 6-O-(2-methyl-butylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-methyl-butylamine (32 mg) and stirred at room temperature for 7 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 114 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.74-5.72 (m, 1H), 5.20 (br t, 1H, J=7.1 Hz), 3.67 (dd, 1H, J=2.8, 1.11 Hz), 3.60-3.40 (m, 5H), 3.47 (s, 3H), 3.01 (d, 1H, J=4.3 Hz), 2.56 (t, 1H, J=6.3 Hz), 2.53 (d, 1H, J=4.3 Hz), 2.50 (t, 2H, J=11.2 Hz), 2.40-1.77 (m, 9H), 1.75 (s, 3H), 1.69 (s, 3H), 1.26 (s, 3H), 1.21-0.95 (m, 10H).
    • EXAMPLE 47 Preparation of 6-O-(2,2-dimethyl-propylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2,2-dimethyl-propylamine (32 mg) and stirred at room temperature for 10 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 103 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.70 (m, 1H), 5.20 (br t, 1H, J=7.2 Hz), 3.67 (dd, 1H, J=2.9, 1.11 Hz), 3.57-3.36 (m, 5H), 3.46 (s, 3H), 3.00 (d, 1H, J=4.1 Hz), 2.60 (t, 1H, J=6.4 Hz), 2.55 (d, 1H, J=4.1 Hz), 2.45-1.80 (m, 10H), 1.71 (s, 3H), 1.66 (s, 3H), 1.23 (s, 3H), 1.01 (s, 9H).
    • EXAMPLE 50 Preparation of 6-O-(1-ethyl-propylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (130 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 1-ethyl-propylamine (32 mg) and stirred at room temperature for 6 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 99 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.71 (m, 1H), 5.19 (br t, 1H, J=7.1 Hz) , 3.68 (dd, 1H, J=2.7, 1.11 Hz), 3.57-3.35 (m, 5H), 3.46 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.58 (t, 1H, J=6.4 Hz), 2.54 (d, 1H, J=4.2 Hz), 2.52 (t, 1H, J=11.0 Hz), 2.46-1.80 (m, 9H), 1.74 (s, 3H), 1.65 (s, 3H), 1.31-1.00 (m, 14H), 1.21 (s, 3H).
    • EXAMPLE 54 Preparation of 6-O-(1-isopropyl-2-methyl-propylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (135 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 1-isopropyl-2-methyl-propylamine (43 mg) and stirred at room temperature for 10 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 97 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.70 (m, 1H), 5.19 (br t, 1H, J=7.0 Hz), 3.65 (dd, 1H, J=2.6, 1.11 Hz), 3.56-3.37 (m, 5H), 3.47 (s, 3H), 3.01 (d, 1H, J=4.3 Hz), 2.60 (t, 1H, J=6.4 Hz), 2.57 (d, 1H, J=4.3 Hz), 2.52 (d, 1H, J=11.2 Hz), 2.47-1.81 (m, 12H), 1.73 (s, 3H), 1.67 (s, 3H), 1.25 (s, 3H), 0.99 (d, 12H, J=10.8 Hz).
    • EXAMPLE 55 Preparation of 6-O-(3-methylbutylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (134 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 3-methylbutylamine (48 mg) and stirred at room temperature for 5 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 111 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.71 (m, 1H), 5.17 (br t, 1H, J=7.0 Hz), 3.66 (dd, 1H, J=2.8, 1.11 Hz), 3.57-3.36 (m, 5H), 3.49 (s, 3H), 3.01 (d, 1H, J=4.2 Hz), 2.60 (t, 1H, J=6.4 Hz), 2.57 (d, 1H, J=4.2 Hz), 2.54-2.52 (m, 1H), 2.46-1.79 (m, 13H), 1.74 (s, 3H), 1.65 (s, 3H), 1.23 (s, 3H), 1.03-0.98 (m, 13H).
    • EXAMPLE 56 Preparation of 6-O-(2-methyl-allylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (129 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-methyl-allylamine (26 mg), and stirred at room temperature for 5 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 105 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.74-5.71 (m, 1H), 5.52-5.48 (m, 2H), 5.21 (br t, 1H, J=7.2 Hz), 3.67 (dd, 1H, J=2.8, 1.11 Hz), 3.59-3.41 (m, 5H), 3.48 (s, 3H), 3.11 (br s, 2H), 3.03 (d, 1H, J=4.3 Hz), 2.57 (t, 1H, J=6.3 Hz), 2.55 (d, 1H, J=4.3 Hz), 2.40-1.77 (m, 13H), 1.79 (s, 3H), 1.74 (s, 3H), 1.65 (s, 3H), 1.22 (s, 3H)
    • EXAMPLE 63 Preparation of 6-O-(cyclopropylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (51.4 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclopropylamine (8 mg) and stirred at room temperature for 8 hours. The reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 38 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.74-5.71 (m, 1H), 5.21 (br t, 1H, J=7.0 Hz), 3.64 (dd, 1H, J=2.7, 1.11 Hz), 3.57-3.39 (m, 5H), 3.48 (s, 3H), 3.00 (d, 1H, J=4.3 Hz), 2.62 (t, 1H, J=6.4 Hz), 2.56 (d, 1H, J=4.3 Hz), 2.47-1.81 (m, 7H), 1.71 (s, 3H), 1.66 (s, 3H), 1.31-1.01 (m, 5H), 1.21 (s, 3H), 0.98-0.87 (m, 1H), 0.55-0.41 (m, 2H).
    • EXAMPLE 64 Preparation of 6-O-(cyclobutylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (50.3 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclobutylamine (10 mg) and stirred at room temperature for 6 hours. The reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 40 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.77-5.70 (m, 1H), 5.20 (br t, 1H, J=7.1 Hz), 3.64 (dd, 1H, J=2.8, 1.11 Hz), 3.56-3.34 (m, 6H), 3.46 (s, 3H), 3.02 (d, 1H, J=4.4 Hz), 2.61 (t, 1H, J=6.4 Hz), 2.56 (d, 1H, J=4.4 Hz), 2.48-2.37 (m, 1H), 2.21-1.60 (m, 17H), 1.74 (s, 3H), 1.64 (s, 3H), 2.22-1.01 (m, 4H), 1.19 (s, 3H).
    • EXAMPLE 65 Preparation of 6-O-(cyclopentylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (51.0 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclopentylamine (12 mg) and stirred at room temperature for 6 hours. The reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 36 mg of the title compound as colorless oil.
  • 1H-NMR (CDCl3) δ: 5.73-5.67 (m, 1H), 5.22 (br t, 1H, J=7.1 Hz), 3.62 (dd, 1H, J=2.8, 1.11 Hz), 3.57-3.36 (m, 5H), 3.44 (s, 3H), 3.21-3.10 (m, 1H), 2.99 (d, 1H, J=4.2 Hz), 2.60 (t, 1H, J=6.7 Hz), 2.55 (d, 1H, J=4.2 Hz), 2.44-2.35 (m, 1H), 2.21-1.60 (m, 15H), 1.74 (s, 3H), 1.64 (s, 3H), 1.56-1.43 (m, 2H), 1.39-1.31 (m, 2H), 1.22-1.01 (m, 4H), 1.20 (s, 3H).
    • EXAMPLE 66 Preparation of 6-O-(cyclohexylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (53.5 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with cyclohexylamine (15 mg) and stirred at room temperature for 6 hours. The reaction was diluted with ethyl acetate (10 ml) and washed with saturated aqueous sodium hydrogen carbonate (3 ml) and saturated brine (3 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 42 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.75-5.68 (m, 1H), 5.19 (br t, 1H, J=7.3 Hz), 3.64 (dd, 1H, J=2.8, 1.10 Hz), 3.57-3.34 (m, 6H), 3.45 (s, 3H), 3.00 (d, 1H, J=4.3 Hz), 2.61 (t, 1H, J=6.7 Hz), 2.55 (d, 1H, J=4.3 Hz), 2.46-2.33 (m, 2H), 2.23-1.57 (m, 14H), 1.76 (s, 3H), 1.63 (s, 3H), 1.36-1.02 (m, 10H), 1.20 (s, 3H).
    • EXAMPLE 67 Preparation of 6-O-(4-tert-butyl-cyclohexylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (128 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 4-tert-butyl-cyclohexylamine (55 mg) and stirred at room temperature for 6 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:10), yielding 104 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.75-5.68 (m, 1H), 5.19 (br t, 1H, J=7.4 Hz), 3.65 (dd, 1H, J=2.7, 11.3 Hz), 3.56-3.35 (m, 6H), 3.46 (s, 3H), 3.03 (d, 1H, J=4.4 Hz), 2.61 (t, 1H, J=6.7 Hz), 2.56 (d, 1H, J=4.4 Hz), 2.46-2.33 (m, 2H), 2.23-1.72 (m, 10H), 1.78 (s, 3H), 1.65 (s, 3H), 1.36-1.19 (m, 4H), 1.21 (s, 3H) , 1.16-0.94 (m, 6H) , 0.82 (s, 9H)
    • EXAMPLE 68 Preparation of 6-O-(2-dimethylamino-1-methylethylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (132 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-dimethylamino-1-methylethylamine (38 mg) and stirred at room temperature for 6 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:5), yielding 104 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.74-5.71 (m, 1H), 5.19 (br t, 1H, J=7.0 Hz), 3.68 (dd, 1H, J=2.7, 1.11 Hz), 3.56-3.37 (m, 5H), 3.49 (s, 3H), 3.03 (d, 1H, J=4.4 Hz), 2.91-2.88 (m, 1H), 2.65 (d, 2H, J=7.8 Hz), 2.61 (t, 1H, J=6.4 Hz), 2.56 (d, 1H, J=4.4 Hz), 2.50 (s, 6H), 2.45-1.76 (m, 10H), 1.74 (s, 3H), 1.66 (s, 3H) , 1.25 (s, 3H) , 1.04 (d, 3H, J=8.1 Hz)
    • EXAMPLE 69 Preparation of 6-O-(2-dimethylamino-propylamino)acetyl fumagillol
  • 6-O-chloroacetyl fumagillol (126 mg), obtained from the above step 1 of the above example 1, was dissolved in dimethylformamide (1 ml), added with 2-dimethyl-propylamine (36 mg) and stirred at room temperature for 7 hours. The reaction was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium hydrogen carbonate (5 ml) and saturated brine (5 ml). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was vacuum concentrated to give the residue, which was purified by silica gel column chromatography (methanol:dichloromethane=1:5), yielding 118 mg of the title compound as a colorless oil.
  • 1H-NMR (CDCl3) δ: 5.75-5.72 (m, 1H), 5.20 (br t, 1H, J=7.0 Hz), 3.66 (dd, 1H, J=2.8, 1.11 Hz), 3.57-3.38 (m, 5H), 3.45 (s, 3H), 3.17-3.14 (m, 1H), 3.01 (d, 1H, J=4.2 Hz), 2.81 (d, 2H, J=8.4 Hz), 2.62 (t, 1H, J=6.4 Hz), 2.57 (d, 1H, J=4.2 Hz), 2.47 (s, 6H), 2.44-1.78 (m, 10H), 1.73 (s, 3H), 1.64 (s, 3H), 1.24 (s, 3H), 1.02 (d, 3H, J=8.6 Hz).
    • EXAMPLES 45, 48, 49, 51-53, 57-62 AND 70-77
  • The fumagillol derivatives, as represented by the formula I, were prepared in the same manner as in the above example 1, except that amine compounds were changed. The results are presented in the following Table 3.
    TABLE 3
    Ex. No. Fumagillol Derivative Amine Compound
    45 6-O-(sec-butylamino)acetyl fumagillol sec-butylamine
    48 6-O-(pentylamino)acetyl fumagillol Pentylamine
    49 6-O-(1-methyl-butylamino)acetyl 1-methyl-butylamine
    fumagillol
    51 6-O-(1-methyl-pentylamino)acetyl 1-methyl-pentylamine
    fumagillol
    52 6-0-(1,2-dimethylbutylamino)acetyl fumagillol 1,2-dimethylbutylamine
    53 6-O-(1,2,2-trimethylpropylamino)acetyl fumagillol 1,2,2-trimethylpropylamine
    54 6-O-(4-methyl-hepta-2,4- 4-methyl-hepta-2,4-
    dienylamino)acetyl fumagillol dienylamine
    58 6-O-(1,5-dimethyl-4-hexenylamino)acetyl 1,5-dimethyl-4-
    fumagillol hexenylamine
    59 6-O-(1,1-dimethyl-2-propinylamino)acetyl 1,1-dimethyl-2-
    fumagillol propinylamine
    60 6-O-(prop-2-enylamino)acetyl fumagillol prop-2-enylamine
    61 6-O-(2-bromoethylamino)acetyl fumagillol 2-bromoethylamine
    62 6-O-(chloroethynylamino)acetyl chloroethynylamine
    fumagillol
    70 6-0-(2-methoxy-2-methyl- 2-methoxy-2-methyl-
    propylamino)acetyl fumagillol propylamine
    71 6-O-(2-oxo-propylamino)acetyl fumagillol 2-oxo-propylamine
    72 6-O-(1,1-dimethyl-3-oxobutylamino)acetyl 1,1-dimethyl-3-
    fumagillol oxobutylamino
    73 6-O-(ethyl-2-aminoacetate)acetyl ethyl-2-aminoacetate
    fumagillol
    74 6-O-(alaninemethylesteramino)acetyl Alaninemethylesteramine
    fumagillol
    75 6-O-(methyl-2-amino-3,3- ethyl-2-amino-3,3-
    dimethylbutanoate)acetyl fumagillol dimethylbutanoate
    76 6-O-(allylglycinemethylester)acetyl Allylglycinemethylester
    fumagillol
    77 6-O-(2,2-dimethoxyethylamino)acetyl 2,2-dimethoxyethylamine
    fumagillol
  • Each of the fumagillol derivatives obtained from the above examples 63 and 64 was treated with the acid, or reacted with the salt in the presence of the acid catalyst, to perform the oxyrane ring-opening reaction.
    • EXAMPLE 78 Preparation of 4-((cyclopropylamino)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol
  • 6-O-(cyclopropylamino)acetyl fumagillol (100 mg), obtained from the above example 63, in tetrahydrofuran (10 ml), was added with hydrochloric acid (0.14 ml) and stirred for 32 hours. The reaction was added with water (10 ml) and ethyl acetate (100 ml). The organic layer was separated, washed with saturated brine (10 ml), dried over anhydrous magnesium sulfate and filtered. Then, the solvent was distilled off under reduced pressure to give the residue, which was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:2), yielding 54 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 5.77-5.70 (m, 1H), 5.20 (br t, 1H, J=7.1 Hz), 3.64 (dd, 1H, J=2.8, 11.1 Hz), 3.56-3.34 (m, 6H), 3.49 (s, 3H), 3.02 (d, 1H, J=4.4 Hz), 2.61 (t, 1H, J=6.4 Hz), 2.56 (d, 1H, J=4.4 Hz), 2.48-2.37 (m, 1H), 2.21-1.60 (m, 17H), 1.74 (s, 3H), 1.64 (s, 3H), 2.22-1.01 (m, 4H), 1.19 (s, 3H)
    • EXAMPLE 79 Preparation of 4-((cyclobutylamino)acetyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol
  • 6-O-(cyclobutylamino)acetyl fumagillol (100 mg), obtained from the above example 64, in tetrahydrofuran (10 ml) was added with chlorolithium (48 mg) and acetic acid (0.12 ml), and stirred at 30° C. for 36 hours. The reaction was added with water (10 ml) and ethyl acetate (100 ml). The organic layer was separated, washed with saturated brine (10 ml), dried over anhydrous magnesium sulfate and filtered. Then, the solvent was distilled off under reduced pressure to give the residue, which was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:2), yielding 49 mg of the title compound as a white solid.
  • 1H-NMR (CDCl3) δ: 5.77-5.70 (m, 1H), 5.20 (br t, 1H, J=7.1 Hz), 3.64 (dd, 1H, J=2.8, 1.11 Hz), 3.56-3.34 (m, 6H), 3.46 (s, 3H), 3.02 (d, 1H, J=4.4 Hz), 2.61 (t, 1H, J=6.4 Hz), 2.56 (d, 1H, J=4.4 Hz), 2.48-2.37 (m, 1H), 2.21-1.60 (m, 17H), 1.74 (S, 3H), 1.64 (s, 3H), 2.22-1.01 (m, 4H), 1.19 (s, 3H).
    • PREPARATION EXAMPLE 1 Preparation of Tablet
  • A tablet containing the fumagillol compound of the present invention as an effective ingredient was prepared according to the following processes.
  • The compound of the above example 1 was sieved, mixed with lactose, starch and pregelatinized corn starch. To the mixture, purified water was added in a suitable volume. The paste was granulated, dried, mixed with magnesium stearate, and then compressed, to obtain the tablet.
  • Such a tablet comprises the following components:
    Compound of example 1  5.0 mg
    Lactose BP 150.0 mg 
    Starch BP 30.0 mg
    Pregelatinized corn starch BP 15.0 mg
    Magnesium stearate  1.0 mg
    • PREPARATION EXAMPLE 2 Preparation of Capsule
  • A capsule containing the fumagillol compound of the present invention as the effective ingredient was prepared as follows.
  • The compound of the example 1 was mixed with a predetermined amount of a vehicle and magnesium state. Thusly obtained mixture was filled in a gelatin capsule.
  • Such a capsule comprises the following components:
    Compound of the example 1 5.0 mg
    Starch 1500 100.0 mg 
    Magnesium sterate BP 1.0 mg
    • PREPARATION EXAMPLE 3 Preparation of Injection
  • An injection containing the fumagillol compound of the present invention as the effective ingredient was prepared as follows.
  • The compound of the example 1 was dissolved in a suitable volume of saline for injection BP. The pH of the resultant solution was controlled with dilute hydrochloric acid BP to be 3.5, and then the solution volume was controlled with saline for injection BP. The solution was filled in 5 ml type 1 ampule made of transparent glass, and the top of ampule was fused for sealing. The solution contained in the ampule was autoclaved at 120° C. for at least 15 minutes to be sterilized, giving the injection.
  • Such an injection comprises the following components:
    Compound of example 1 100 μg/ml
    Dilute hydrochloric acid BP to be pH 3.5
    Saline for injection BP maximal 1 ml
    • EXPERIMENTAL EXAMPLE 1 Inhibitory Effect of Fumagillol Derivative on Cell Growth
  • Using the HUVECs (human umbilical vein endothelial), the effect of the fumagillol derivative of the present invention on cell growth was evaluated.
  • The HUVECs were added to M199 medium supplemented with 20% FBS (fetal bovine serum), 100 U/ml penicillin, 100 μg/ml streptomycin, 1.5 g/L sodium bicarbonate, 0.1 mg/ml endothelial cell growth supplement (Sigma) and 0.1 mg/ml heparin (Sigma), after which the cells were incubated in an incubator at 37° C. under 5% CO2. Cells were subcultured a maximum of 8 times before being discarded.
  • In order to evaluate inhibitory activity of the fumagillin derivative on growth of HUVECs, the inventive compound was dissolved in DMSO and its concentration was adjusted from 10 mM to 1 mM. Cells were aliquotted to 96 well plates at a density of 2×103 cells per well and incubated for about 12-24 hours to be properly attached to the plate. Thereafter, the medium was replaced with new medium. The cells were treated with the compound obtained from each of the above examples at various concentration ranges of from 10 μM to 0.001 ρM, and cultured for 2-3 days, followed by removing 100 μl of the medium from each well.
  • Colorimetry was performed to determine the extent of cell growth. The cells on each plate was added with 20 μl of aqueous one solution and then incubated at 37° C. under 5% CO2 for 2 hours. Using a 96-well plate reader, absorption was measured at 490 nm. The results are given in Table 4, below.
  • As such, a conventional TNP-470 having angiogenesis inhibitory effect was used as a control.
    TABLE 4
    Compound IC50 (η g/ml)
    TNP-470 29
    EX. 1 0.0071
    EX. 2 0.15
    EX. 3 0.09
    EX. 4 0.08
    EX. 5 142
    EX. 6 19
    EX. 7 21
    EX. 8 42
    EX. 9 0.63
    EX. 10 0.06
    EX. 11 0.08
    EX. 12 0.07
    EX. 13 0.016
    EX. 14 14
    EX. 15 0.06
    EX. 16 0.17
    EX. 17 0.61
    EX. 18 17
    EX. 19 174
    EX. 20 162
    EX. 21 185
    EX. 22 179
    EX. 23 0.24
    EX. 24 181
    EX. 25 0.31
    EX. 26 179
    EX. 27 88
    EX. 28 102
    EX. 29 178
    EX. 30 0.09
    EX. 31 0.06
    EX. 32 128
    EX. 33 109
    EX. 34 98
    EX. 35 116
    EX. 36 0.021
    EX. 37 0.017
    EX. 38 0.019
    EX. 39 0.019
    EX. 40 0.18
    EX. 41 20
    EX. 42 12
    EX. 43 2400
    EX. 44 3200
    EX. 45 370
    EX. 46 2600
    EX. 47 16
    EX. 48 3000
    EX. 49 44
    EX. 50 24
    EX. 51 32000
    EX. 52 290
    EX. 53 162
    EX. 54 11
    EX. 55 17
    EX. 56 28
    EX. 57 420
    EX. 58 415
    EX. 59 174
    EX. 60 185
    EX. 61 2800
    EX. 62 340
    EX. 63 0.008
    EX. 64 0.07
    EX. 65 250
    EX. 66 0.6
    EX. 67 0.06
    EX. 68 240
    EX. 69 260
    EX. 70 178
    EX. 71 260
    EX. 72 330
    EX. 73 1200
    EX. 74 800
    EX. 75 2400
    EX. 76 1490
    EX. 77 330
    EX. 78 0.014
    EX. 79 0.037
    Intermediate 2000
  • From the above Table 4, it can be seen that the inventive compound exhibits superior inhibitory effect on cell proliferation, compared to conventionally known fumagillin. In particular, the compound in which R1 is aromatic is superior in angiogenesis inhibitory effect to the compound in which R1 is aliphatic. For instance, in the case where R1 is aromatic, 6-O-(4-methoxyaniline)acetyl fumagillol of the above example 1 has excellent inhibitory effect, 2000 times greater than known TNP-470. In the case where R1 is aliphatic, 6-O-(cyclopropylamino)acetyl fumagillol and 6-O-(4-(cyclobutylamino)acetyl fumagillol of the above examples 63 and 64, respectively, are 100-1000 times higher in inhibitory effect on HUVEC, compared to TNP-470.
    • EXPERIMENTAL EXAMPLE 2 Acute Toxicity Test for Oral Administration of Fumagillol Derivative using Rats
  • To investigate acute toxicity of the compound of the formula I, the following experiment was performed.
  • Using 6-week-old specific pathogen-free (SPF) Sprague-Dawley rats, acute toxicity was tested. Each of the compounds obtained from the above examples was suspended in 0.5% methylcelluose solution, and orally administered once to every two rats constituting each group in the dose of 1 g/kg/15 ml. After administration, mortality, clinical symptoms and body weight of the tested animals were observed. Hematological and blood-biochemical tests were carried out. The animals were dissected and abnormal conditions of pleural cavity and abdominal cavity were observed with the naked eye. As the test result, there were no specifically abnormal symptoms in any of the tested animals and no mortality. In addition, toxicity indicators were not observed in the body weight, hematological and blood-biochemical tests, or by dissection.
  • The present compounds did not show toxicity up to the amounts of 2 g/kg for all rats, and the minimal lethal dose (LD50) of each compound in case of oral administration was 2 g/kg or more, thus the present compound was evaluated as a safe compound.
    • INDUSTRIAL APPLICABILITY
  • As described hereinbefore, the compound of the formula I of the present invention is advantageous in light of excellent angiogenesis inhibitory effect and low toxicity, and is usefully applicable as an angiogenesis inhibitory agent. As well, the inventive compound can inhibit cancer metastasis and treat cancer, rheumatic arthritis, psoriasis and diabetic retinopathy, which are associated with angiogenesis regarded as a pathogenic phenomenon.
  • The present invention has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

Claims (2)

1: A pharmaceutical composition for inhibition of angiogenesis, comprising a therapeutically effective amount of a fumagillol compound represented by the following formula I or a pharmaceutically acceptable salt thereof, as an effective ingredient:
Figure US20060276512A1-20061207-C00096
wherein,
X is —OH and Y is halogen, or X and Y are linked together to form an oxyrane ring,
B represents —(C═O)— or —CH2—,
R1 represents hydroxy; —CN; —NO2; —CF3; formyl; C1-C4 thioalkyl; acetamido; acetoxy; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 alkyloxycarboxylic acid; C3-C6 cycloalkyl or
Figure US20060276512A1-20061207-C00097
in which R2, R3, R4, R5 and R6, which are the same or different, each represents hydrogen; hydroxy; —CN; —NO2; —CF3; formyl; C1-C4 thioalkyl; acetamido; acetoxy; C1-C6 alkyl; C1-C4 aminoalkyl; C1-C4 alkylaminoalkyl; C1-C4 dialkylaminoalkyl; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 hydroxyalkyl; or C1-C4 alkyloxycarboxylic acid; or, R2 and R3, R3 and R4, R4 and R5, or R5 and R6, are linked together to form a C1-C3 alkylene dioxy ring, and
Z1, Z2, Z3, Z4 and Z5 each represent carbon or nitrogen.
2: A pharmaceutical compound for treatment of cancer, rheumatoid arthritis, psoriasis or diabetic retinopathy, or for inhibition of cancer metastasis, comprising a therapeutically effective amount of a fumagillol compound represented by the following formula I or a pharmaceutically acceptable salt thereof, as an effective ingredient:
Figure US20060276512A1-20061207-C00098
wherein,
X is —OH and Y is halogen, or X and Y are linked together to form an oxyrane ring,
B represents —(C═O)— or —CH2—,
R1 represents hydroxy; —CN; —NO2; —CF3; formyl; C1-C4 thioalkyl; acetamido; acetoxy; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 alkyloxycarboxylic acid; C3-C6 cycloalkyl or
Figure US20060276512A1-20061207-C00099
in which R2, R3, R4, R5 and R6, which are the same or different, each represents hydrogen; hydroxy; —CN; —NO2; —CF3; formyl; C1-C4 thioalkyl; acetamido; acetoxy; C1-C6 alkyl; C1-C4 aminoalkyl; C1-C4 alkylaminoalkyl; C1-C4 dialkylaminoalkyl; C1-C6 alkoxy; C1-C6 aminoalkoxy; C1-C4 alkylaminoalkoxy; C1-C4 dialkylaminoalkoxy; amino; C1-C6 alkylamino; C1-C4 dialkylamino; C1-C4 hydroxyalkyl; or C1-C4 alkyloxycarboxylic acid; or, R2 and R3, R3 and R4, R4 and R5, or R5 and R6, are linked together to form a C1-C3 alkylene dioxy ring, and
Z1, Z2, Z3, Z4 and Z5 each represent carbon or nitrogen.
US11/494,026 2001-09-27 2006-07-26 Fumagillol derivatives and preparing method thereof Abandoned US20060276512A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/494,026 US20060276512A1 (en) 2001-09-27 2006-07-26 Fumagillol derivatives and preparing method thereof
US11/603,688 US20070149613A1 (en) 2001-09-27 2006-11-21 Fumagillol derivative and the medical use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KRKR2001-60017 2001-09-27
KR10-2001-0060017A KR100455900B1 (en) 2001-09-27 2001-09-27 Novel fumagillol derivatives and preparing method thereof
KR10-2002-0029915A KR100483836B1 (en) 2002-05-29 2002-05-29 Novel fumagillol derivatives and preparing method thereof
KRKR2002-29915 2002-05-29
US10/490,588 US7087768B2 (en) 2001-09-27 2002-06-11 Fumagillol derivatives and preparing method thereof
US11/494,026 US20060276512A1 (en) 2001-09-27 2006-07-26 Fumagillol derivatives and preparing method thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/490,588 Division US7087768B2 (en) 2001-09-27 2002-06-11 Fumagillol derivatives and preparing method thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/603,688 Continuation-In-Part US20070149613A1 (en) 2001-09-27 2006-11-21 Fumagillol derivative and the medical use thereof

Publications (1)

Publication Number Publication Date
US20060276512A1 true US20060276512A1 (en) 2006-12-07

Family

ID=26639368

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/490,588 Expired - Fee Related US7087768B2 (en) 2001-09-27 2002-06-11 Fumagillol derivatives and preparing method thereof
US11/494,026 Abandoned US20060276512A1 (en) 2001-09-27 2006-07-26 Fumagillol derivatives and preparing method thereof
US11/603,688 Abandoned US20070149613A1 (en) 2001-09-27 2006-11-21 Fumagillol derivative and the medical use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/490,588 Expired - Fee Related US7087768B2 (en) 2001-09-27 2002-06-11 Fumagillol derivatives and preparing method thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/603,688 Abandoned US20070149613A1 (en) 2001-09-27 2006-11-21 Fumagillol derivative and the medical use thereof

Country Status (5)

Country Link
US (3) US7087768B2 (en)
EP (1) EP1436286B1 (en)
AT (1) ATE440094T1 (en)
DE (1) DE60233420D1 (en)
WO (1) WO2003027104A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016425A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8349891B2 (en) 2010-11-09 2013-01-08 Zafgen, Inc. Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
US8367721B2 (en) 2008-12-04 2013-02-05 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A3 (en) * 2011-10-03 2013-07-04 Zafgen Corporation Methods of treating age related disorders
US20130216494A1 (en) * 2010-05-25 2013-08-22 SynDecRx, Inc. Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof
US8772333B2 (en) 2010-01-08 2014-07-08 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US8980946B2 (en) 2010-11-29 2015-03-17 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
US9067905B2 (en) 2009-10-09 2015-06-30 Zafgen, Inc. Sulphone compounds and methods of making and using same
US9173956B2 (en) 2013-04-10 2015-11-03 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
US9266896B2 (en) 2010-07-22 2016-02-23 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9328082B2 (en) 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9561209B2 (en) 2012-11-05 2017-02-07 Zafgen, Inc. Methods of treating liver diseases
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
US9649293B2 (en) 2010-04-07 2017-05-16 Zafgen, Inc. Methods of treating an overweight subject
US9656979B2 (en) 2008-12-04 2017-05-23 Zafgen, Inc. Methods of treating an overweight or obese subject
US9682965B2 (en) 2015-08-11 2017-06-20 Zafgen, Inc. Fumagillol heterocyclic compounds and methods of making and using same
US9839622B2 (en) 2012-05-08 2017-12-12 Zafgen, Inc. Methods of treating hypothalamic obesity
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9944613B2 (en) 2015-08-11 2018-04-17 Zafgen, Inc. Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US10646463B2 (en) 2016-01-11 2020-05-12 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1436286B1 (en) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
KR100552043B1 (en) * 2004-02-28 2006-02-20 주식회사종근당 Composition for obesity treatment comprising fumagillol derivatives
US20100056623A1 (en) * 2005-01-26 2010-03-04 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
EP2170402B1 (en) 2007-06-26 2015-03-25 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US8399512B2 (en) * 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
FR2973376B1 (en) * 2011-03-28 2013-05-10 Atlanthera DERIVATIVES USEFUL IN THE TREATMENT OR PREVENTION OF BONE TUMORS
TW201636342A (en) * 2014-12-19 2016-10-16 武田藥品工業有限公司 Fumagillol derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846562A (en) * 1996-04-01 1998-12-08 Takeda Chemical Industries, Ltd. Oral composition of fumagillol derivative
US6040337A (en) * 1998-05-15 2000-03-21 Chong Kun Dang Corporation 5-demethoxyfumagillol derivatives and processes for preparing the same
US7087768B2 (en) * 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) * 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
EP0357061B1 (en) 1988-09-01 1994-06-08 Takeda Chemical Industries, Ltd. Angiogenesis inhibitory agent
KR0138530B1 (en) * 1988-09-01 1998-05-15 우메모또 요시마사 Fumagillol derivatives
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
EP0387650B1 (en) 1989-03-06 1993-03-31 Takeda Chemical Industries, Ltd. 6-epifumagillols, production and use thereof
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (en) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
DE19653036A1 (en) 1996-12-19 1998-06-25 Merck Patent Gmbh Cyclopeptide derivatives
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
BR0013143A (en) 1999-08-12 2002-06-11 Pharmacia Italia Spa 3 (5) amino pyrazole derivatives, process for their preparation and use as antitumor agents
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
WO2003037330A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846562A (en) * 1996-04-01 1998-12-08 Takeda Chemical Industries, Ltd. Oral composition of fumagillol derivative
US6040337A (en) * 1998-05-15 2000-03-21 Chong Kun Dang Corporation 5-demethoxyfumagillol derivatives and processes for preparing the same
US7087768B2 (en) * 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016425A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8865746B2 (en) * 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8367721B2 (en) 2008-12-04 2013-02-05 Zafgen, Inc. Methods of treating an overweight or obese subject
US9656979B2 (en) 2008-12-04 2017-05-23 Zafgen, Inc. Methods of treating an overweight or obese subject
US9701651B2 (en) 2008-12-04 2017-07-11 Zafgen, Inc. Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US9067905B2 (en) 2009-10-09 2015-06-30 Zafgen, Inc. Sulphone compounds and methods of making and using same
US9067913B2 (en) 2010-01-08 2015-06-30 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
US8772333B2 (en) 2010-01-08 2014-07-08 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US10406134B2 (en) 2010-04-07 2019-09-10 Zafgen, Inc. Methods of treating an overweight subject
US9649293B2 (en) 2010-04-07 2017-05-16 Zafgen, Inc. Methods of treating an overweight subject
US9730955B2 (en) 2010-05-25 2017-08-15 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US20130216494A1 (en) * 2010-05-25 2013-08-22 SynDecRx, Inc. Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof
US9320805B2 (en) * 2010-05-25 2016-04-26 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US10722532B2 (en) 2010-05-25 2020-07-28 Syndevrx, Inc. Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof
US10159692B2 (en) 2010-05-25 2018-12-25 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9585909B2 (en) 2010-05-25 2017-03-07 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9839623B2 (en) 2010-07-22 2017-12-12 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9266896B2 (en) 2010-07-22 2016-02-23 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US8349891B2 (en) 2010-11-09 2013-01-08 Zafgen, Inc. Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
US9827221B2 (en) 2010-11-09 2017-11-28 Zafgen, Inc. Crystalline solids of a metAP-2 inhibitor and methods of making and using same
US9371312B2 (en) 2010-11-09 2016-06-21 Zafgen, Inc. Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
US8735447B2 (en) 2010-11-09 2014-05-27 Zafgen, Inc. Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
US9000035B2 (en) 2010-11-29 2015-04-07 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
US8980946B2 (en) 2010-11-29 2015-03-17 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
US9173865B2 (en) 2010-11-29 2015-11-03 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9328082B2 (en) 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
US10259796B2 (en) 2011-03-08 2019-04-16 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
US9617237B2 (en) 2011-05-06 2017-04-11 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9446016B2 (en) 2011-10-03 2016-09-20 Zafgen, Inc. Methods of treating age related disorders
WO2013055385A3 (en) * 2011-10-03 2013-07-04 Zafgen Corporation Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
US9839622B2 (en) 2012-05-08 2017-12-12 Zafgen, Inc. Methods of treating hypothalamic obesity
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
US9895339B2 (en) 2012-05-09 2018-02-20 Zafgen, Inc. Fumigillol compounds and methods of making and using same
US10220015B2 (en) 2012-05-09 2019-03-05 Zafgen, Inc. Fumigillol compounds and methods of making and using same
US10064839B2 (en) 2012-11-05 2018-09-04 Zafgen, Inc. Methods of treating liver diseases
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
US9561209B2 (en) 2012-11-05 2017-02-07 Zafgen, Inc. Methods of treating liver diseases
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
US9849106B2 (en) 2013-03-14 2017-12-26 Zafgen, Inc. Methods of treating impaired wound healing
US10231946B2 (en) 2013-03-14 2019-03-19 Zafgen, Inc. Methods of treating ischemic organ damage and other disorders
US9757373B2 (en) 2013-04-10 2017-09-12 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
US10010544B2 (en) 2013-04-10 2018-07-03 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
US11304944B2 (en) 2013-04-10 2022-04-19 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
US9750737B2 (en) 2013-04-10 2017-09-05 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
US9433600B2 (en) 2013-04-10 2016-09-06 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
US9173956B2 (en) 2013-04-10 2015-11-03 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
US10588904B2 (en) 2013-04-10 2020-03-17 Syndevrx, Inc. METAP2 inhibitors and methods of treating obesity
US9682965B2 (en) 2015-08-11 2017-06-20 Zafgen, Inc. Fumagillol heterocyclic compounds and methods of making and using same
US9944613B2 (en) 2015-08-11 2018-04-17 Zafgen, Inc. Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same
US10023561B2 (en) 2015-08-11 2018-07-17 Zafgen, Inc. Fumagillol heterocyclic compounds and methods of making and using same
US10287277B2 (en) 2015-12-10 2019-05-14 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
US10646463B2 (en) 2016-01-11 2020-05-12 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11273142B2 (en) 2016-01-11 2022-03-15 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Also Published As

Publication number Publication date
EP1436286B1 (en) 2009-08-19
US7087768B2 (en) 2006-08-08
US20040242681A1 (en) 2004-12-02
EP1436286A4 (en) 2004-12-15
DE60233420D1 (en) 2009-10-01
ATE440094T1 (en) 2009-09-15
US20070149613A1 (en) 2007-06-28
WO2003027104A1 (en) 2003-04-03
EP1436286A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
US20060276512A1 (en) Fumagillol derivatives and preparing method thereof
CA2331873C (en) Fumagillol derivatives and processes for preparing the same
US6040337A (en) 5-demethoxyfumagillol derivatives and processes for preparing the same
CA1329771C (en) Angiogenesis inhibitory agent
US7250439B2 (en) Matrix metalloproteinase inhibitors
US20100056623A1 (en) Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
JP2006504621A (en) Carbamate esters as HIV protease inhibitors
HU182019B (en) Process for producing n-alkyl-aminoalcohols
JP2009102371A (en) Triptolide analog for treatment of autoimmune diseases and inflammatory disorders
EP0090344B1 (en) 1,3-dioxolen-2-one derivatives and process for production thereof
CN101827811A (en) NSC 630176 and preparation thereof and purposes
PT94121A (en) PROCESS FOR THE PREPARATION OF PHENOL DERIVATIVES TO PROMOTE THE HUMAN NERVE GROWTH FACTOR
JPH03218367A (en) Naphthyloxazolidone derivative, its production and intermediate for synthesizing the same
JP2004525082A5 (en)
JP6929866B2 (en) 2,3-Epoxy succinyl derivative, its preparation method and use
JPH07330761A (en) Substituted chroman
EP0157623B1 (en) Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease
JP4365102B2 (en) NOVEL SULFONAMIDE DERIVATIVE, INTERMEDIATE COMPOUND THEREOF, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SULFONAMIDE DERIVATIVE
KR100455900B1 (en) Novel fumagillol derivatives and preparing method thereof
JPH05221938A (en) Substituted aminopropane, preparation thereof and use thereof
KR20010053076A (en) Hydroxamic Acid Derivatives as Inhibitors of the Production of Human CD23 and of the TNF Release
EP0083256B1 (en) Benzamide derivatives
JPH11147876A (en) Tetrahydroisoquinoline derivative and medicine containing the same as active ingredient
KR100483836B1 (en) Novel fumagillol derivatives and preparing method thereof
CN112961081B (en) Bibenzamide urea compound and preparation method and application thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION